

### PERSONAL INFORMATION **DELIA GOLETTI**

#### WORK EXPERIENCE

---

June 1999- Present **Head of the Translational Research Unit**  
Istituto Nazionale per le Malattie Infettive L. Spallanzani-IRCCS (Italy)  
Prof Goletti has research and clinical activities.

#### RESEARCH ACTIVITIES

She is the head of the Translational Research Unit, with 13 members (3 seniors, 4 post-doc, 1 research nurse, 1 technician, 2 student technicians, 2 recently graduated biologists).

Her current research interests are on the immune pathogenesis, immune diagnostic tests and immune response in tuberculosis, echinococcosis and COVID-19. She is interested also in host-directed therapies for COVID-19 and tuberculosis. She is among the most cited scientists worldwide for tuberculosis and COVID-19 research with 298 publications up to now.

Her main expertise is on the discovery of biomarkers and set-up of immune diagnostic tests, on host directed therapy for TB and COVID-19.

#### CLINICAL ACTIVITIES (2 days/week)

Management of patients with tuberculosis, non tuberculosis mycobacteria.

Management of patients with tuberculosis and co-infections (HIV, COVID-19, HCV, HBV).

Management of patients with latent tuberculosis infection that are candidates for biologic therapy ( patients with rheumatological, dermatological, neurological pathologies)

Management of patients with cystic Echinococcosis.

Collaboration with the service that takes care of the Health Care Workers at INMI.

I

October 1996-May 1999 **Staff Scientist**  
Istituto superiore di Sanità (Italy)  
Research on immune correlate of protection for a SHIV vaccines based on tat DNA or tat protein in a monkey model; Research on on the role of HHV-8 on the pathogenesis of Kaposi sarcoma

#### EDUCATION AND TRAINING

---

October 1984-July 1990 **Medical Degree**  
Università Cattolica del Sacro Cuore (Italy)  
Medical Degree

January 1991-October 1995 **PhD in Infectivology**  
Università Cattolica del Sacro Cuore (Italy)  
PhD In Infectious Disease. Thesis done at the Laboratory of Immune Regulation (LIR) at the National Institute of Health, Bethesda, Maryland, USA directed by A.S. Fauci

January 1994-September 1997 **specialization in Infectious Diseases**  
Università Cattolica del sacro Cuore (Italy)

#### ADDITIONAL INFORMATION

---

**Expertise** Main expertise is on:  
Tuberculosis (TB) pathogenesis, TB clinical management, TB biomarkers discovery, immune diagnostic tests for TB,

TB-HIV coinfection clinical management and pathogenesis,  
 impact of biological therapy on infection diseases, impact of biological therapy and small molecules on TB reactivation,  
 sputum microbiota and TB  
 impact of M. tuberculosis on autophagy  
 host directed therapy for TB and COVID-19  
 Echinococcosis immune diagnostic tests, immune pathogenesis of Echinococcosis, Echinococcosis clinical management,  
 COVID-19 immune response, COVID-19-TB clinical issues, COVID-19 new therapeutical approaches, immune diagnostic tests for COVID-19  
 Member of Scientific International Boards as an expert representative  
 1. Member del Scientific Advisory Board of Deutsches Zentrum fur Infektionsforschung (DZIF), Germany <https://www.dzif.de/en> for the tuberculosis field  
 2. Scientific Board Member of the TuBerculosis Vaccine Initiative (TBVI), a Research and Innovation partnership that facilitates the discovery and development of new, safe and effective TB vaccines that are accessible and affordable for all people.

## Publications REFERENCES

<https://pubmed.ncbi.nlm.nih.gov/?term=goletti+d&sort=date&size=100>

1. Fornaro M, Stano S, Goletti D, Semeraro A, Cantatore FP, Maruotti N, Colella S, Abbruzzese A, Santo L, Praino E, Iannone F. Prevalence and management of tuberculosis infection in Apulian rheumatologic patients treated with biologics: an observational cohort 10-year study from the BIOPURE registry. *Eur J Clin Invest.* 2022 Nov 27:e13913. doi: 10.1111/eci.13913. Epub ahead of print. PMID: 36435984
2. Farroni C, Aiello A, Picchianti-Diamanti A, Lagana B, Petruccioli E, Agrati C, Garbuglia AR, Meschi S, Lapa D, Cuzzi G, Petrone L, Vanini V, Salmi A, Altera AMG, Repele F, Grassi G, Bettini A, Vita S, Mariano A, Damiani A, Infantino M, Grossi V, Manfredi M, Niccoli L, Puro V, Rosa RD, Salemi S, Sesti G, Scolieri P, Bruzzese V, Benucci M, Cantini F, Nicastrì E, Goletti D. Booster dose of SARS-CoV-2 messenger RNA vaccines strengthens the specific immune response of patients with rheumatoid arthritis: A prospective multicenter longitudinal study. *Int J Infect Dis.* 2022 Nov 1;125:195-208. doi: 10.1016/j.ijid.2022.10.035. Epub ahead of print. PMID: 36328289; PMCID: PMC9622025.
3. Migliori GB, Matteelli A, Zenner D, Goletti D, Ong CWM. Reply to Furin et al.: Clinical standards that are appropriate for all settings. *Int J Tuberc Lung Dis.* 2022 Nov 1;26(11):1093-1094. doi: 10.5588/ijtld.22.0452. PMID: 36281054.
4. Najafi-Fard S, Petruccioli E, Farroni C, Petrone L, Vanini V, Cuzzi G, Salmi A, Altera AMG, Navarra A, Alonzi T, Nicastrì E, Palmieri F, Gualano G, Carlini V, Noonan DM, Albini A, Goletti D. Evaluation of the immunomodulatory effects of interleukin-10 on peripheral blood immune cells of COVID-19 patients: Implication for COVID-19 therapy. *Front Immunol.* 2022 Sep 6;13:984098. doi: 10.3389/fimmu.2022.984098. PMID: 36148228; PMCID: PMC9486547.
5. Canetti D, Antonello RM, Saderi L, Giro M, Goletti D, Sarmati L, Rodari P, Bocchino M, Schiro M, Riccardi N, Sotgiu G. Impact of SARS-CoV-2 infection on tuberculosis outcome and follow-up in Italy during the first COVID-19 pandemic wave: a nationwide online survey. *Infez Med.* 2022 Sep 1;30(3):418-426. doi: 10.53854/liim-3003-10. PMID: 36148161; PMCID: PMC9448321.
6. Ruibal P, Franken KLMC, van Meijgaarden KE, van Wolfswinkel M, Derksen I, Scheeren FA, Janssen GMC, van Veelen PA, Sarfas C, White AD, Sharpe SA, Palmieri F, Petrone L, Goletti D, Abeel T, Ottenhoff THM, Joosten SA. Identification of HLA-E Binding Mycobacterium tuberculosis-Derived Epitopes through Improved Prediction Models. *J Immunol.* 2022 Sep 12;jj2200122. doi: 10.4049/jimmunol.2200122. Epub ahead of print. PMID: 36096642.
7. Compagno M, Navarra A, Campogiani L, Coppola L, Rossi B, Iannetta M, Malagnino V, Parisi SG, Mariotti B, Cerretti R, Arcese W, Goletti D, Andreoni M, Sarmati L. Latent Tuberculosis Infection in Haematopoietic Stem Cell Transplant Recipients: A Retrospective Italian Cohort Study in Tor Vergata University Hospital, Rome. *Int J Environ Res Public Health.* 2022 Aug 27;19(17):10693. doi: 10.3390/ijerph191710693. PMID: 36078409; PMCID: PMC9518118.
8. Garcia-Garcia JM, Blanc FX, Buonsenso D, Centis R, Codecasa LR, D'Ambrosio L, Goletti D,

- Gualano G, Kunst H, Pontali E, Tadolini M, Tiberi S, Ong CWM, Sotgiu G, Migliori GB; Global Tuberculosis Network. COVID-19 Hampered Diagnosis of TB Infection in France, Italy, Spain and the United Kingdom. *Arch Bronconeumol*. 2022 Aug 13;S0300-2896(22)00503-8. doi: 10.1016/j.arbres.2022.07.013. Epub ahead of print. PMID: 36064681; PMCID: PMC9393764.
9. Vita S, Rosati S, Ascoli Bartoli T, Beccacece A, D'Abramo A, Mariano A, Scorzoloni L, Goletti D, Nicastrì E. Monoclonal Antibodies for Pre- and Postexposure Prophylaxis of COVID-19: Review of the Literature. *Pathogens*. 2022 Aug 5;11(8):882. doi: 10.3390/pathogens11080882. PMID: 36015003; PMCID: PMC9412407.
10. Aiello A, Grossi A, Meschi S, Meledandri M, Vanini V, Petrone L, Casetti R, Cuzzi G, Salmi A, Altera AM, Pierelli L, Gualano G, Ascoli Bartoli T, Castilletti C, Agrati C, Girardi E, Palmieri F, Nicastrì E, Di Rosa E, Goletti D. Coordinated innate and T-cell immune responses in mild COVID-19 patients from household contacts of COVID-19 cases during the first pandemic wave. *Front Immunol*. 2022 Jul 27;13:920227. doi: 10.3389/fimmu.2022.920227. PMID: 35967321; PMCID: PMC9364317.
11. Aiello A, Coppola A, Vanini V, Petrone L, Cuzzi G, Salmi A, Altera AM, Tortorella C, Gualano G, Gasperini C, Scolieri P, Beccacece A, Vita S, Bruzzese V, Lorenzetti R, Palmieri F, Nicastrì E, Goletti D. Accuracy of QuantiFERON SARS-CoV-2 RUO assay and characterization of the CD4+ and CD8+ T-cell-SARS-CoV-2 response: comparison with a homemade IFN- release assay. *Int J Infect Dis*. 2022 Jul 22;122:841-9. doi: 10.1016/j.ijid.2022.07.049. Epub ahead of print. PMID: 35878802; PMCID: PMC9307287.
12. Petrone L, Tortorella C, Aiello A, Farroni C, Ruggieri S, Castilletti C, Meschi S, Cuzzi G, Vanini V, Palmieri F, Prosperini L, Haggiag S, Galgani S, Grifoni A, Sette A, Gasperini C, Nicastrì E, Goletti D. Humoral and Cellular Response to Spike of Delta SARS-CoV-2 Variant in Vaccinated Patients With Multiple Sclerosis. *Front Neurol*. 2022 May 31;13:881988. doi: 10.3389/fneur.2022.881988. PMID: 35711277; PMCID: PMC9194677.
13. Alonzi T, Aiello A, Repele F, Falasca L, Francalancia M, Garbuglia AR, Delogu G, Nicastrì E, Piacentini M, Goletti D. Cysteamine exerts in vitro antiviral activity against the SARS-CoV-2 Delta and Omicron variants. *Cell Death Discov*. 2022 Jun 15;8(1):288. doi: 10.1038/s41420-022-01080-8. PMID: 35705564; PMCID: PMC9199336.
14. Bergeron A, Mikulska M, De Greef J, Bondeelle L, Franquet T, Herrmann JL, Lange C, Spriet I, Akova M, Donnelly JP, Maertens J, Maschmeyer G, Rovira M, Goletti D, de la Camara R; European Conference on Infections in Leukaemia group. Mycobacterial infections in adults with haematological malignancies and haematopoietic stem cell transplants: guidelines from the 8th European Conference on Infections in Leukaemia. *Lancet Infect Dis*. 2022 May 27;S1473-3099(22)00227-4. doi: 10.1016/S1473-3099(22)00227-4. Epub ahead of print. PMID: 35636446.
15. Guglielmetti L, Gunther G, Leu C, Cirillo D, Duarte R, Garcia-Basteiro AL, Goletti D, Jankovic M, Kuksa L, Maurer FP, Mechai F, Tiberi S, van Leth F, Veziris N, Lange C; Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC), European Society of Mycobacteriology (ESM), European Respiratory Society (ERS) and; Tuberculosis Network European Trials group (TBnet). Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. *Eur Respir J*. 2022 May 19;59(5):2200388. doi: 10.1183/13993003.00388-2022. Print 2022 May. PMID: 35589114 Free PMC article.
16. Migliori GB, Thong PM, Alffenaar JW, Denholm J, Tadolini M, Alyaquobi F, Al-Abri S, Blanc FX, Buonsenso D, Chakaya J, Cho JG, Codecasa LR, Danila E, Duarte R, Dukpa R, Garcia-Garcia JM, Gualano G, Kurhasani X, Manika K, Mello FCQ, Pahl K, Rendon A, Sotgiu G, Souleymane MB, Thomas TA, Tiberi S, Kunst H, Udawadia ZF, Goletti D, Centis R, D'Ambrosio L, Silva DR. Country-specific lockdown measures in response to the COVID-19 pandemic and its impact on tuberculosis control: a global study. *J Bras Pneumol*. 2022 Apr 20;48(2):e20220087. English, Portuguese. doi: 10.36416/1806-3756/e20220087. PMID: 35475873.
17. Petrone L, Picchianti-Diamanti A, Sebastiani GD, Aiello A, Lagana B, Cuzzi G, Vanini V, Gualano G, Grifoni A, Ferraioli M, Castilletti C, Meschi S, Vaia F, Nicastrì E, Sette A, Goletti D. Humoral and cellular responses to spike of SARS-CoV-2 variant in vaccinated patients with Immune Mediated Inflammatory Diseases. *Int J Infect Dis*. 2022 Apr 21;S1201-9712(22)00229-6. doi: 10.1016/j.ijid.2022.04.027. Epub ahead of print. PMID: 35462039; PMCID: PMC9023365.
18. Agrati C, Castilletti C, Goletti D, Sacchi A, Bordoni V, Mariotti D, Notari S, Matusali G, Meschi S, Petrone L, Aiello A, Najafi Fard S, Farroni C, Colavita F, Lapa D, Leone S, Agresta A, Capobianchi M, Ippolito G, Vaia F, Puro V; INMI COVID-19 Vaccine Study Group. Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine. *Sci Rep*. 2022 Apr 23;12(1):6687. doi: 10.1038/s41598-022-07741-z. PMID: 35461335; PMCID: PMC9034067.

19. Shu Q, Liu S, Alonzi T, LaCourse SM, Singh DK, Bao D, Wamalwa D, Jiang L, Lyon CJ, John-Stewart G, Kaushal D, Goletti D, Hu T. Assay design for unambiguous identification and quantification of circulating pathogen-derived peptide biomarkers. *Theranostics*. 2022 Mar 21;12(6):2948-2962. doi: 10.7150/thno.70373. PMID: 35401822; PMCID: PMC8965485.
20. Chedid C, Andrieu T, Kokhreizze E, Tukvadze N, Biswas S, Ather MF, Uddin MKM, Banu S, De Maio F, Delogu G, Endtz H, Goletti D, Vocanson M, Dumitrescu O, Hoffmann J, Ader F. In-Depth Immunophenotyping With Mass Cytometry During TB Treatment Reveals New T-Cell Subsets Associated With Culture Conversion. *Front Immunol*. 2022 Mar 22;13:853572. doi: 10.3389/fimmu.2022.853572. PMID: 35392094; PMCID: PMC8980213.
21. Dahl VN, Tiberi S, Goletti D, Wejse C. Armed conflict and human displacement may lead to an increase in the burden of tuberculosis in Europe. *Int J Infect Dis*. 2022 Mar 29:S1201-9712(22)00180-1. doi: 10.1016/j.ijid.2022.03.040. Epub ahead of print. PMID: 35364284.
22. La Manna MP, Orlando V, Badami GD, Tamburini B, Shekarkar Azgomi M, Lo Presti E, Del Nonno F, Petrone L, Belmonte B, Falasca L, Di Carlo P, Dieli F, Goletti D, Caccamo N. Platelets accumulate in lung lesions of tuberculosis patients and inhibit T-cell responses and Mycobacterium tuberculosis replication in macrophages. *Eur J Immunol*. 2022 Mar 26. doi: 10.1002/eji.202149549. Epub ahead of print. PMID: 35338775.
23. Margineanu I, Rustage K, Noori T, Zenner D, Greenaway C, Pareek M, Akkerman O, Hayward S, Friedland JS, Goletti D, Stienstra Y, Hargreaves S; ESGITM/ESGMYC Study Groups. Country-specific approaches to latent tuberculosis screening targeting migrants in EU/EEA\* countries: A survey of national experts, September 2019 to February 2020. *Euro Surveill*. 2022 Mar;27(12):2002070. doi: 10.2807/1560-7917.ES.2022.27.12.2002070. PMID: 35332865; PMCID: PMC8950856.
24. Migliori GB, Falzon D, Marks GB, Goletti D, Kasaeva T, Esposito S, Humbert M. Commemorating World Tuberculosis Day 2022: recent ERJ articles of critical relevance to ending TB and saving lives. *Eur Respir J*. 2022 Mar 24;59(3):2200149. doi: 10.1183/13993003.00149-2022. PMID: 35332091.
25. Di Bari V, Gualano G, Musso M, Libertone R, Nisii C, Ianniello S, Mosti S, Mastrobattista A, Cerva C, Bevilacqua N, Iacomi F, Mondì A, Topino S, Goletti D, Girardi E, Palmieri F, On Behalf Of The Tb-Inmi Working Group. Increased Association of Pulmonary Thromboembolism and Tuberculosis during COVID-19 Pandemic: Data from an Italian Infectious Disease Referral Hospital. *Antibiotics (Basel)*. 2022 Mar 16;11(3):398. doi: 10.3390/antibiotics11030398. PMID: 35326861; PMCID: PMC8944753.
26. Farroni C, Picchianti-Diamanti A, Aiello A, Nicastrì E, Lagana B, Agrati C, Castilletti C, Meschi S, Colavita F, Cuzzi G, Casetti R, Grassi G, Petrone L, Vanini V, Salmi A, Repele F, Altera AMG, Maffongelli G, Corpolongo A, Salemi S, Di Rosa R, Nalli G, Sesti G, Vaia F, Puro V, Goletti D. Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis. *Front Immunol*. 2022 Feb 28;13:846753. doi: 10.3389/fimmu.2022.846753. PMID: 35309297; PMCID: PMC8924958.
27. Tunesi S, Du DL, Gualano G, Millet JP, Skrahin A, Bothamley G, Casas X, Goletti D, Lange C, Musso M, Palmieri F, Pourcher V, Rioux C, Skrahina A, Veziris N, Viatushka D, Jachym-Frechet M, Guglielmetti L; TBnet, The ESGMYC, and The French MDR-TB Group. Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection: a TBnet and ESGMYC study. *J Infect*. 2022 Mar 7:S0163-4453(22)00130-X. doi: 10.1016/j.jinf.2022.03.004. Epub ahead of print. PMID: 35271917.
28. Melkie ST, Arias L, Farroni C, Jankovic Makek M, Goletti D, Vilaplana C. The role of antibodies in tuberculosis diagnosis, prophylaxis and therapy: a review from the ESGMYC study group. *Eur Respir Rev*. 2022 Mar 9;31(163):210218. doi: 10.1183/16000617.0218-2021. PMID: 35264411.
29. Goletti D, Delogu G, Matteelli A, Migliori GB. The role of IGRA in the diagnosis of tuberculosis infection, differentiating from active tuberculosis, and decision making for initiating treatment or preventive therapy of tuberculosis infection. *Int J Infect Dis*. 2022 Mar 4:S1201-9712(22)00126-6. doi: 10.1016/j.ijid.2022.02.047. Epub ahead of print. PMID: 35257904.
30. Petersen E, Al-Abri S, Chakaya J, Goletti D, Parolina L, Wejse C, Mucheleng'anga LA, Khalili SA, Yeboah-Manu D, Chanda-Kapata P, Nasiri MJ, Lungu PS, Maeurer M, Tiberi S, Ntoumi F, Battista-Migliori G, Zumla A. World TB Day 2022: Revamping and Reshaping Global TB Control Programs by Advancing Lessons learnt from the COVID-19 pandemic. *Int J Infect Dis*. 2022 Mar 3:S1201-9712(22)00138-2. doi: 10.1016/j.ijid.2022.02.057. Epub ahead of print. PMID: 35248715; PMCID: PMC8894685.
31. Migliori GB, Wu SJ, Matteelli A, Zenner D, Goletti D, Ahmedov S, Al-Abri S, Allen DM, Balcells

- ME, Garcia-Basteiro AL, Cambau E, Chaisson RE, Chee CBE, Dalcolmo MP, Denholm JT, Erkens C, Esposito S, Farnia P, Friedland JS, Graham S, Hamada Y, Harries AD, Kay AW, Kritski A, Manga S, Marais BJ, Menzies D, Ng D, Petrone L, Rendon A, Silva DR, Schaaf HS, Skrahina A, Sotgiu G, Thwaites G, Tiberi S, Tukvadze N, Zellweger JP, D'Ambrosio L, Centis R, Ong CWM. Clinical standards for the diagnosis, treatment and prevention of TB infection. *Int J Tuberc Lung Dis.* 2022 Mar 1;26(3):190-205. doi: 10.5588/ijtld.21.0753. PMID: 35197159; PMCID: PMC8886963.
32. Margineanu I, Akkerman O, Cattaneo D, Goletti D, Marriott DJE, Migliori GB, Mirzayev F, Peloquin CA, Stienstra Y, Alffenaar JW. Practices of therapeutic drug monitoring in tuberculosis - an international survey. *Eur Respir J.* 2022 Jan 27;2102787. doi: 10.1183/13993003.02787-2021. Epub ahead of print. PMID: 35086830.
33. Ferraccioli G, Gremese E, Goletti D, Petrone L, Cantini F, Ugel S, Cane S, Bronte V. Immune-guided therapy of COVID-19. *Cancer Immunol Res.* 2022 Jan 24;canimm.0675.2021. doi: 10.1158/2326-6066.CIR-21-0675. Epub ahead of print. PMID: 35074758.
34. Migliori GB, Ong CWM, Petrone L, D'Ambrosio L, Centis R, Goletti D. The definition of tuberculosis infection based on the spectrum of tuberculosis disease. *Breathe (Sheff).* 2021 Sep;17(3):210079. doi: 10.1183/20734735.0079-2021. PMID: 35035549; PMCID: PMC8753649.
35. Alonzi T, Aiello A, Petrone L, Najafi Fard S, D'Eletto M, Falasca L, Nardacci R, Rossin F, Delogu G, Castilletti C, Capobianchi MR, Ippolito G, Piacentini M, Goletti D. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy. *Cells.* 2021 Dec 24;11(1):52. doi: 10.3390/cells11010052. PMID: 35011614; PMCID: PMC8750154.
36. Petruccioli E, Farroni C, Cuzzi G, Vanini V, Palmieri F, Vittozzi P, Goletti D. VIDAS(R) TB-IGRA reagents induce a CD4+ and CD8+ T-cell IFN- response for both TB infection and active TB. *Int J Tuberc Lung Dis.* 2022 Jan 1;26(1):65-68. doi: 10.5588/ijtld.21.0478. PMID: 34969431; PMCID: PMC8734189.
37. Cantini F, Goletti D, Benucci M, Foti R, Damiani A, Niccoli L. Tailored first-line biologic and targeted synthetic disease modifying anti-rheumatic drugs therapy in patients with rheumatoid arthritis: 2021 updated ITABIO statements. *Expert Opin Drug Saf.* 2021 Dec 29;1-11. doi: 10.1080/14740338.2022.2020247. Epub ahead of print. PMID: 34937466.
38. Montaldo C, Messina F, Abbate I, Antonioli M, Bordoni V, Aiello A, Ciccocanti F, Colavita F, Farroni C, Najafi Fard S, Giombini E, Goletti D, Matusali G, Rozera G, Rueca M, Sacchi A, Piacentini M, Agrati C, Fimia GM, Capobianchi MR, Lauria FN, Ippolito G. Multi-omics approach to COVID-19: a domain-based literature review. *J Transl Med.* 2021 Dec 7;19(1):501. doi: 10.1186/s12967-021-03168-8. PMID: 34876157; PMCID: PMC8649311.
39. Tortorella C, Aiello A, Gasperini C, Agrati C, Castilletti C, Ruggieri S, Meschi S, Matusali G, Colavita F, Farroni C, Cuzzi G, Cimini E, Tartaglia E, Vanini V, Prosperini L, Haggiag S, Galgani S, Quartuccio ME, Salmi A, Repele F, Gerarda Altera AM, Cristofanelli F, D'Abramo A, Bevilacqua N, Corpolongo A, Puro V, Vaia F, Capobianchi MR, Ippolito G, Nicastrì E, Goletti D; INMI COVID-19 Vaccine Study Group. Humoral- and T-Cell-Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies. *Neurology.* 2021 Nov 22;10.1212/WNL.0000000000013108. doi: 10.1212/WNL.0000000000013108.
40. Opota O, Mazza-Stalder J, Viveiros M, Cambau E, Santin M, Goletti D. Editorial: Tuberculosis and Non-tuberculous Mycobacteria Infections: Control, Diagnosis and Treatment. *Front Public Health.* 2021 Oct 28;9:666187. doi: 10.3389/fpubh.2021.666187. PMID: 34778160; PMCID: PMC8581263.
41. TB/COVID-19 Global Study Group. Tuberculosis and COVID-19 co-infection: description of the global cohort. *Eur Respir J.* 2021 Nov 11;2102538. doi: 10.1183/13993003.02538-2021. Miotto P, Goletti D, Petrone L. Making IGRA testing easier: First performance report of QIAreacH QFT for tuberculosis infection diagnosis. *Pulmonology.* 2021 Oct 28;S2531-0437(21)00195-1. doi: 10.1016/j.pulmoe.2021.07.010.
42. Perez-Recio S, Pallares N, Grijota-Camino MD, Sanchez-Montalva A, Barcia L, Campos-Gutierrez S, Pomar V, Rabunal-Rey R, Balcells ME, Gazel D, Montiel N, Vicente D, Goic-Barisic I, Schon T, Paues J, Marekovic I, Cacho-Calvo J, Barac A, Goletti D, Garcia-Gasalla M, Barcala JM, Tortola MT, Anibarro L, Suarez-Toste I, Moga E, Gude-Gonzalez MJ, Naves R, Karstligil T, Martin-Penaranda T, Stevanovic G, Trigo M, Rubio V, Karaoglan I, Bayram N, Alcaide F, Tebe C, Santin M; ESCMID Study Group for Mycobacterial Infections (ESGMYC) and the Mycobacteria Study Group (GEIM) of the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC). Identification of Recent Tuberculosis Exposure Using QuantiFERON-TB Gold Plus, a Multicenter Study. *Microbiol Spectr.* 2021 Nov 10;9(3):e0097221. doi: 10.1128/Spectrum.00972-21. Epub ahead of print.



43. D'Offizi G, Agrati C, Visco-Comandini U, Castilletti C, Puro V, Piccolo P, Montalbano M, Meschi S, Tartaglia E, Sorace C, Leone S, Lapa D, Grassi G, Goletti D, Ippolito G, Vaia F, Ettorre GM, Lionetti R. Coordinated cellular and humoral immune responses after two-dose SARS-CoV2 mRNA vaccination in liver transplant recipients. *Liver Int.* 2021 Oct 31. doi: 10.1111/liv.15089. Epub ahead of print. PMID: 34719107.
44. Delemarre EM, van Hoorn L, Bossink AWJ, Drylewicz J, Joosten SA, Ottenhoff THM, Akkerman OW, Goletti D, Petruccioli E, Navarra A, van den Broek BTA, Paardekooper SPA, van Haeften I, Koenderman L, Lammers JJ, Thijsen SFT, Hofland RW, Nierkens S. Serum Biomarker Profile Including CCL1, CXCL10, VEGF, and Adenosine Deaminase Activity Distinguishes Active From Remotely Acquired Latent Tuberculosis. *Front Immunol.* 2021 Oct 7;12:725447. doi: 10.3389/fimmu.2021.725447. PMID: 34691031; PMCID: PMC8529994.
45. Picchianti-Diamanti A, Aiello A, Lagana B, Agrati C, Castilletti C, Meschi S, Farroni C, Lapa D, Najafi Fard S, Cuzzi G, Cimini E, Grassi G, Vanini V, Di Rosa R, Salemi S, Nalli G, Salmi A, Repele F, Altera AMG, Maffongelli G, Palazzolo C, Vita S, Leone S, Puro V, Capobianchi MR, Ippolito G, Nicastrì E, Goletti D. Immunosuppressive Therapies Differently Modulate Humoral- and T-Cell-Specific Responses to COVID-19 mRNA Vaccine in Rheumatoid Arthritis Patients. *Front Immunol.* 2021 Sep 14;12:740249. doi: 10.3389/fimmu.2021.740249. PMID: 34594343; PMCID: PMC8477040.
46. Petruccioli E, Petrone L, Chiacchio T, Farroni C, Cuzzi G, Navarra A, Vanini V, Massafra U, Lo Pizzo M, Guggino G, Caccamo N, Cantini F, Palmieri F, Goletti D. Mycobacterium tuberculosis Immune Response in Patients With Immune-Mediated Inflammatory Disease. *Front Immunol.* 2021 Aug 10;12:716857. doi: 10.3389/fimmu.2021.716857. PMID: 34447382; PMCID: PMC8382688.
47. Migliori GB, Thong PM, Alffenaar JW, Denholm J, Tadolini M, Alyaquobi F, Blanc FX, Buonsenso D, Cho JG, Ruffo Codecasa L, Danila E, Duarte R, Garcia-Garcia JM, Gualano G, Rendon A, Rossato Silva D, Souleymane MB, Tham SM, Thomas TA, Tiberi S, Udawadia ZF, Goletti D, Centis R, D'Ambrosio L, Sotgiu G, Ong CWM; Global Tuberculosis Network. Gauging the impact of the COVID-19 pandemic on tuberculosis services: a global study. *Eur Respir J.* 2021 Aug 26:2101786. doi: 10.1183/13993003.01786-2021. Epub ahead of print. PMID: 34446465.
48. Petrone L, Tamarozzi F, Vola A, Gomez Morales MA, Ludovisi A, Najafi Fard S, Mariconti M, Brunetti E, Goletti D. Accuracy of an experimental whole-blood test for detecting reactivation of echinococcal cysts. *PLoS Negl Trop Dis.* 2021 Aug 20;15(8):e0009648. doi: 10.1371/journal.pntd.0009648. PMID: 34415898; PMCID: PMC8378729.
49. Rustage K, Lobe J, Hayward SE, Kristensen KL, Margineanu I, Stienstra Y, Goletti D, Zenner D, Noori T, Pareek M, Greenaway C, Friedland JS, Nellums LB, Hargreaves S; ESGITM and ESGMYC study groups. Initiation and completion of treatment for latent tuberculosis infection in migrants globally: a systematic review and meta-analysis. *Lancet Infect Dis.* 2021 Aug 4:S1473-3099(21)00052-9. doi: 10.1016/S1473-3099(21)00052-9. Epub ahead of print. PMID: 34363771.
50. Minardi ML, Fato I, Di Gennaro F, Mosti S, Mastrobattista A, Cerva C, Libertone R, Saracino A, Goletti D, Girardi E, Andreoni M, Palmieri F, Gualano G. Common and Rare Hematological Manifestations and Adverse Drug Events during Treatment of Active TB: A State of Art. *Microorganisms.* 2021 Jul 9;9(7):1477. doi: 10.3390/microorganisms9071477. PMID: 34361913; PMCID: PMC8304680.
51. Bohrer AC, Castro E, Hu Z, Queiroz ATL, Tocheny CE, Assmann M, Sakai S, Nelson C, Baker PJ, Ma H, Wang L, Zilu W, du Bruyn E, Riou C, Kauffman KD; Tuberculosis Imaging Program, Moore IN, Del Nonno F, Petrone L, Goletti D, Martineau AR, Lowe DM, Cronan MR, Wilkinson RJ, Barry CE, Via LE, Barber DL, Klion AD, Andrade BB, Song Y, Wong KW, Mayer-Barber KD. Eosinophils are part of the granulocyte response in tuberculosis and promote host resistance in mice. *J Exp Med.* 2021 Oct 4;218(10):e20210469. doi: 10.1084/jem.20210469. Epub 2021 Aug 4. PMID: 34347010; PMCID: PMC8348215.
52. Grace PS, Dolatshahi S, Lu LL, Cain A, Palmieri F, Petrone L, Fortune SM, Ottenhoff THM, Lauffenburger DA, Goletti D, Joosten SA, Alter G. Antibody Subclass and Glycosylation Shift Following Effective TB Treatment. *Front Immunol.* 2021 Jul 5;12:679973. doi: 10.3389/fimmu.2021.679973. PMID: 34290702; PMCID: PMC8287567.
53. Goletti D, Petrone L, Manissero D, Bertoletti A, Rao S, Ndunda N, Sette A, Nikolayevskyy V. The potential clinical utility of measuring SARS-CoV-2-specific T-cell responses. *Clin Microbiol Infect.* 2021 Jul 10:S1198-743X(21)00378-5. doi: 10.1016/j.cmi.2021.07.005. Epub ahead of print. PMID: 34256141; PMCID: PMC8272618.
54. Najafi Fard S, Petrone L, Petruccioli E, Alonzi T, Matusali G, Colavita F, Castilletti C,

- Capobianchi MR, Goletti D. In Vitro Models for Studying Entry, Tissue Tropism, and Therapeutic Approaches of Highly Pathogenic Coronaviruses. *Biomed Res Int.* 2021 Jun 21;2021:8856018. doi: 10.1155/2021/8856018. PMID: 34239932; PMCID: PMC8221881.
55. Bayaa R, Ndiaye MDB, Chedid C, Kokhraidze E, Tukvadze N, Banu S, Uddin MKM, Biswas S, Nasrin R, Ranaivomanana P, Raheerinandrasana AH, Rakotonirina J, Rasolofo V, Delogu G, De Maio F, Goletti D, Endtz H, Ader F, Hamze M, Ismail MB, Pouzol S, Rakotosamimanana N, Hoffmann J; HINTT working group within the GABRIEL network. Multi-country evaluation of RISK6, a 6-gene blood transcriptomic signature, for tuberculosis diagnosis and treatment monitoring. *Sci Rep.* 2021 Jul 1;11(1):13646. doi: 10.1038/s41598-021-93059-1. PMID: 34211042; PMCID: PMC8249600.
56. Agrati C, Castilletti C, Goletti D, Meschi S, Sacchi A, Matusali G, Bordoni V, Petrone L, Lapa D, Notari S, Vanini V, Colavita F, Aiello A, Agresta A, Farroni C, Grassi G, Leone S, Vaia F, Capobianchi MR, Ippolito G, Puro V, On Behalf Of The Inmi Covid-Vaccine Study Group. Coordinate Induction of Humoral and Spike Specific T-Cell Response in a Cohort of Italian Health Care Workers Receiving BNT162b2 mRNA Vaccine. *Microorganisms.* 2021 Jun 16;9(6):1315. doi: 10.3390/microorganisms9061315. PMID: 34208751; PMCID: PMC8235087.
57. Puro V, Castilletti C, Agrati C, Goletti D, Leone S, Agresta A, Cimini E, Tartaglia E, Casetti R, Colavita F, Meschi S, Matusali G, Lapa D, Najafi Fard S, Aiello A, Farrone C, Galli P, Capobianchi MR, Ippolito G, On Behalf Of The Inmi Covid-Vaccine Study Group. Impact of Prior Influenza and Pneumococcal Vaccines on Humoral and Cellular Response to SARS-CoV-2 BNT162b2 Vaccination. *Vaccines (Basel).* 2021 Jun 8;9(6):615. doi: 10.3390/vaccines9060615. PMID: 34201065; PMCID: PMC8229609.
58. Petruccioli E, Najafi Fard S, Navarra A, Petrone L, Vanini V, Cuzzi G, Gualano G, Pierelli L, Bertolotti A, Nicastrì E, Palmieri F, Ippolito G, Goletti D. Exploratory analysis to identify the best antigen and the best immune biomarkers to study SARS-CoV-2 infection. *J Transl Med.* 2021 Jun 26;19(1):272. doi: 10.1186/s12967-021-02938-8. PMID: 34174875; PMCID: PMC8235902.
59. Belleudi V, Rosa AC, Poggi FR, Armuzzi A, Nicastrì E, Goletti D, Diamanti AP, Davoli M, Agabiti N, Addis A. Direct and Indirect Impact of COVID-19 for Patients with Immune-Mediated Inflammatory Diseases: A Retrospective Cohort Study. *J Clin Med.* 2021 May 28;10(11):2388. doi: 10.3390/jcm10112388. PMID: 34071452; PMCID: PMC8197915
60. Grassi G, Vanini V, De Santis F, Romagnoli A, Aiello A, Casetti R, Cimini E, Bordoni V, Notari S, Cuzzi G, Mosti S, Gualano G, Palmieri F, Fraziano M, Goletti D, Agrati C, Sacchi A. PMN-MDSC Frequency Discriminates Active Versus Latent Tuberculosis and Could Play a Role in Counteracting the Immune-Mediated Lung Damage in Active Disease. *Front Immunol.* 2021 Apr 26;12:594376. doi: 10.3389/fimmu.2021.594376. PMID: 33981297; PMCID: PMC8107479.
61. Occhigrossi L, Rossin F, D'Eletto M, Farrace MG, Ciccossanti F, Petrone L, Sacchi A, Nardacci R, Falasca L, Del Nonno F, Palucci I, Smirnov E, Barlev N, Agrati C, Goletti D, Delogu G, Fimia GM, Piacentini M. Transglutaminase 2 Regulates Innate Immunity by Modulating the STING/TBK1/IRF3 Axis. *J Immunol.* 2021 May 15;206(10):2420-2429. doi: 10.4049/jimmunol.2001122. Epub 2021 May 3. PMID: 33941660.
62. D'Abramo A, Vita S, Maffongelli G, Mariano A, Agrati C, Castilletti C, Goletti D, Ippolito G, Nicastrì E; Spallanzani COVID-19 Case Investigation Team. Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: A tailored approach. *Int J Infect Dis.* 2021 Apr 24;107:247-250. doi: 10.1016/j.ijid.2021.04.068. Epub ahead of print. PMID: 33901654; PMCID: PMC8065233.
63. Aiello A, Najafi Fard S, Petruccioli E, Petrone L, Vanini V, Farroni C, Cuzzi G, Navarra A, Gualano G, Mosti S, Pierelli L, Nicastrì E, Goletti D. Spike is the most recognized antigen in the whole-blood platform in both acute and convalescent COVID-19 patients. *Int J Infect Dis.* 2021 May;106:338-347. doi: 10.1016/j.ijid.2021.04.034. Epub 2021 Apr 14. PMID: 33864921; PMCID: PMC8045417.
64. Di Gennaro F, Gualano G, Timelli L, Vittozzi P, Di Bari V, Libertone R, Cerva C, Pinnarelli L, Nisii C, Ianniello S, Mosti S, Bevilacqua N, Iacomì F, Mondì A, Topino S, Goletti D, Vaia F, Ippolito G, Girardi E, Palmieri F. Increase in Tuberculosis Diagnostic Delay during First Wave of the COVID-19 Pandemic: Data from an Italian Infectious Disease Referral Hospital. *Antibiotics (Basel).* 2021 Mar 8;10(3):272. doi: 10.3390/antibiotics10030272. PMID: 33800406; PMCID: PMC7998965.
65. Novelli G, Liu J, Biancolella M, Alonzi T, Novelli A, Patten JJ, Cocciadiferro D, Agolini E, Colona VL, Rizzacasa B, Giannini R, Bigio B, Goletti D, Capobianchi MR, Grelli S, Mann J, McKee TD, Cheng K, Amanat F, Krammer F, Guarracino A, Pepe G, Tomino C, Tandjaoui-Lambiotte Y, Uzunhan Y, Tubiana S, Ghosn J; COVID Human Genetic Effort; French COVID Cohort Study

- Group; CoV- Contact Cohort, Notarangelo LD, Su HC, Abel L, Cobat A, Elhanan G, Grzymiski JJ, Latini A, Sidhu SS, Jain S, Davey RA, Casanova JL, Wei W, Pandolfi PP. Inhibition of HECT E3 ligases as potential therapy for COVID-19. *Cell Death Dis.* 2021 Mar 24;12(4):310. doi: 10.1038/s41419-021-03513-1. PMID: 33762578; PMCID: PMC7987752.
66. Zumla A, Chakaya J, Khan M, Fatima R, Wejse C, Al-Abri S, Fox GJ, Nachega J, Kapata N, Knipper M, Orcutt M, Gosce L, Abubakar I, Nagu TJ, Mugusi F, Gordon AK, Shanmugam S, Bachmann NL, Lam C, Sintchenko V, Rudolf F, Amanullah F, Kock R, Haider N, Lipman M, King M, Maeurer M, Goletti D, Petrone L, Yaqoob A, Tiberi S, Ditiu L, Sahu S, Marais B, Issayeva AM, Petersen E. World Tuberculosis Day 2021 Theme - 'The Clock is Ticking' - and the world is running out of time to deliver the United Nations General Assembly commitments to End TB due to the COVID-19 pandemic. *Int J Infect Dis.* 2021 Mar 18:S1201-9712(21)00264-2. doi: 10.1016/j.ijid.2021.03.046. Epub ahead of print. PMID: 33746094.
67. Petrone L, Petruccioli E, Vanini V, Cuzzi G, Gualano G, Vittozzi P, Nicastrì E, Maffongelli G, Grifoni A, Sette A, Ippolito G, Migliori GB, Palmieri F, Goletti D. Coinfection of tuberculosis and COVID-19 limits the ability to in vitro respond to SARS-CoV-2. *Int J Infect Dis.* 2021 Mar 10:S1201-9712(21)00176-4. doi: 10.1016/j.ijid.2021.02.090. Epub ahead of print. PMID: 33713816; PMCID: PMC7944764.
68. Goletti D, Cantini F. Baricitinib Therapy in Covid-19 Pneumonia - An Unmet Need Fulfilled. *N Engl J Med.* 2021 Mar 4;384(9):867-869. doi: 10.1056/NEJMe2034982. PMID: 33657299.
69. Petrone L, Petruccioli E, Alonzi T, Vanini V, Cuzzi G, Najafi Fard S, Castilletti C, Palmieri F, Gualano G, Vittozzi P, Nicastrì E, Lepore L, Grifoni A, Antinori A, Vergori A, Ippolito G, Cantini F, Goletti D. In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy. *J Infect.* 2021 Feb 25:S0163-4453(21)00094-3. doi: 10.1016/j.jinf.2021.02.023. Epub ahead of print. PMID: 33639176; PMCID: PMC7904476.
70. Chedid C, Kokhredze E, Tukvadze N, Banu S, Uddin MKM, Biswas S, Russomando G, Acosta CCD, Arenas R, Ranaivomanana PP, Razafimahatratra C, Herindrany P, Rakotonirina J, Raheerindrana AH, Rakotosamimanana N, Hamze M, Ismail MB, Bayaa R, Berland JL, De Maio F, Delogu G, Endtz H, Ader F, Goletti D, Hoffmann J. Relevance of QuantiFERON-TB Gold Plus and Heparin-Binding Hemagglutinin Interferon- Release Assays for Monitoring of Pulmonary Tuberculosis Clearance: A Multicentered Study. *Front Immunol.* 2021 Feb 2;11:616450. doi: 10.3389/fimmu.2020.616450. PMID: 33603746; PMCID: PMC7885528.
71. Visca D, Ong CWM, Tiberi S, Centis R, D'Ambrosio L, Chen B, Mueller J, Mueller P, Duarte R, Dalcolmo M, Sotgiu G, Migliori GB, Goletti D. Tuberculosis and COVID-19 interaction: A review of biological, clinical and public health effects. *Pulmonology.* 2021 Jan 22:S2531-0437(21)00004-0. doi: 10.1016/j.pulmoe.2020.12.012. Epub ahead of print. PMID: 33547029; PMCID: PMC7825946.
72. Musso M, Di Gennaro F, Gualano G, Mosti S, Cerva C, Fard SN, Libertone R, Di Bari V, Cristofaro M, Tonnarini R, Castilletti C, Goletti D, Palmieri F. Concurrent cavitary pulmonary tuberculosis and COVID-19 pneumonia with in vitro immune cell anergy. *Infection.* 2021 Jan 17:1-4. doi: 10.1007/s15010-021-01576-y. Epub ahead of print. PMID: 33454928; PMCID: PMC7811686.
73. Vita S, Di Bari V, Corpolongo A, Goletti D, Espinosa J, Petracca S, Palmieri F, Nicastrì E; INMI COVID-19 study groups. Down Syndrome patients with COVID-19 pneumonia: A high-risk category for unfavourable outcome. *Int J Infect Dis.* 2021 Feb;103:607-610. doi: 10.1016/j.ijid.2020.11.188. Epub 2020 Nov 30. PMID: 33271290; PMCID: PMC7703224.
74. Stebbing J, Sanchez Nievas G, Falcone M, Youhanna S, Richardson P, Ottaviani S, Shen JX, Sommerauer C, Tiseo G, Ghiadoni L, Viridis A, Monzani F, Rizos LR, Forfori F, Avendano Cespedes A, De Marco S, Carrozzi L, Lena F, Sanchez-Jurado PM, Lacerenza LG, Cesira N, Caldevilla Bernardo D, Perrella A, Niccoli L, Mendez LS, Matarrese D, Goletti D, Tan YJ, Monteil V, Dranitsaris G, Cantini F, Farcomeni A, Dutta S, Burley SK, Zhang H, Pistello M, Li W, Romero MM, Andres Pretel F, Simon-Talero RS, Garcia-Molina R, Kutter C, Felce JH, Nizami ZF, Miklosi AG, Penninger JM, Menichetti F, Mirazimi A, Abizanda P, Lauschke VM. JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality. *Sci Adv.* 2021 Jan 1;7(1):eabe4724. doi: 10.1126/sciadv.abe4724. PMID: 33187978; PMCID: PMC7775747.
75. Cantini F, Goletti D, Petrone L, Najafi Fard S, Niccoli L, Foti R. Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review. *Drugs.* 2020 Dec;80(18):1929-1946. doi: 10.1007/s40265-020-01421-w. PMID: 33068263; PMCID: PMC7568461.
76. Petrone L, Petruccioli E, Vanini V, Cuzzi G, Fard SN, Alonzi T, Castilletti C, Palmieri F, Gualano G, Vittozzi P, Nicastrì E, Lepore L, Antinori A, Vergori A, Caccamo N, Cantini F, Girardi E, Ippolito G, Grifoni A, Goletti D. A whole blood test to measure SARS-CoV-2 specific response in COVID-19 patients. *Clin Microbiol Infect.* 2020 Oct 10:S1198-743X(20)30605-4. doi: 10.1016/j.cmi.2020.09.051. Epub ahead of print. PMID: 33045370.



77. Sala C, Benjak A, Goletti D, Banu S, Mazza-Stadler J, Jatou K, Busso P, Remm S, Leleu M, Rougemont J, Palmieri F, Cuzzi G, Butera O, Vanini V, Kabir S, Rahman SMM, Nicod L, Cole ST. Multicenter analysis of sputum microbiota in tuberculosis patients. *PLoS One*. 2020 Oct 12;15(10):e0240250. doi: 10.1371/journal.pone.0240250. PMID: 33044973.
78. Mechai F, Cordel H, Guglielmetti L, Aubry A, Jankovic M, Viveiros M, Santin M, Goletti D, Cambau E. Management of Tuberculosis: Are the Practices Homogeneous in High-Income Countries? *Front Public Health*. 2020 Sep 4;8:443. doi: 10.3389/fpubh.2020.00443. PMID: 33014963; PMCID: PMC7509453.
79. Chedid C, Kokhredze E, Tukvadze N, Banu S, Uddin MKM, Biswas S, Russomando G, Acosta CCD, Arenas R, Ranaivomanana PP, Razafimahatratra C, Herindrainy P, Rakotosamimanana N, Hamze M, Ismail MB, Bayaa R, Berland JL, Delogu G, Endtz H, Ader F, Goletti D, Hoffmann J; HINTT working group within the GABRIEL network. Association of baseline white blood cell counts with tuberculosis treatment outcome: a prospective multicentered cohort study. *Int J Infect Dis*. 2020 Sep 10;100:199-206. doi: 10.1016/j.ijid.2020.09.017. Epub ahead of print. PMID: 32920230.
80. Migliori GB, Thong PM, Akkerman O, Alffenaar JW, Alvarez-Navascues F, Assao- Neino MM, Bernard PV, Biala JS, Blanc FX, Bogorodskaya EM, Borisov S, Buonsenso D, Calnan M, Castellotti PF, Centis R, Chakaya JM, Cho JG, Codecasa LR, D'Ambrosio L, Denholm J, Enwerem M, Ferrarese M, Galvao T, Garcia-Clemente M, Garcia-Garcia JM, Gualano G, Gullon-Blanco JA, Inwentarz S, Ippolito G, Kunst H, Maryandyshev A, Melazzini M, de Queiroz Mello FC, Munoz-Torrico M, Njung'fuyini PB, Palmero DJ, Palmieri F, Piccioni P, Piubello A, Rendon A, Sabria J, Saporiti M, Scognamiglio P, Sharma S, Silva DR, Souleymane MB, Spanevello A, Tabernerero E, Tadolini M, Tchangou ME, Thornton ABY, Tiberi S, Udwadia ZF, Sotgiu G, Ong CWM, Goletti D. Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January-April 2020. *Emerg Infect Dis*. 2020 Sep 11;26(11). doi: 10.3201/eid2611.203163. Epub ahead of print. PMID: 32917293.
81. Falasca L, Nardacci R, Colombo D, Lalle E, Di Caro A, Nicastrì E, Antinori A, Petrosillo N, Marchioni L, Biava G, D'Offizi G, Palmieri F, Goletti D, Zumla A, Ippolito G, Piacentini M, Del Nonno F. Post-Mortem Findings in Italian Patients with COVID-19 - a Descriptive Full Autopsy Study of cases with and without co- morbidities. *J Infect Dis*. 2020 Sep 11;jiaa578. doi: 10.1093/infdis/jiaa578. Epub ahead of print. PMID: 32914853; PMCID: PMC7543426.
82. Schon T, Koser CU, Werngren J, Viveiros M, Georghiou S, Kahlmeter G, Giske C, Maurer F, Lina G, Turnidge J, van Ingen J, Jankovic M, Goletti D, Cirillo DM, Santin M, Cambau E; ESGMYC. What is the role of the EUCAST reference method for MIC testing of the Mycobacterium tuberculosis complex? *Clin Microbiol Infect*. 2020 Aug 6:S1198-743X(20)30445-6. doi: 10.1016/j.cmi.2020.07.037. Epub ahead of print. PMID: 32768492.
83. Cantini F, Niccoli L, Nannini C, Matarrese D, Natale MED, Lotti P, Aquilini D, Landini G, Cimolato B, Pietro MAD, Trezzi M, Stobbione P, Frausini G, Navarra A, Nicastrì E, Sotgiu G, Goletti D. Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study. *J Infect*. 2020 Jun 24:S0163-4453(20)30433-3. doi: 10.1016/j.jinf.2020.06.052. Online ahead of print. PMID: 32592703 Free PMC article.
84. Tadolini M, Garcia-Garcia JM, Blanc FX, Borisov S, Goletti D, Motta I, Codecasa LR, Tiberi S, Sotgiu G, Migliori GB; GTN TB/COVID group. On Tuberculosis and COVID-19 co-infection. *Eur Respir J*. 2020 Jun 25:2002328. doi: 10.1183/13993003.02328-2020. Online ahead of print. PMID: 32586888 Free PMC article.
85. Catherine Wei Min Ong Giovanni Battista Migliori, Mario Raviglione, Gavin MacGregor-Skinner, Giovanni Sotgiu, Jan-Willem Alffenaar, Simon Tiberi, Cornelia Adlhoch, Tonino Alonzi, Sophia Archuleta, Sergio Brusin, Emmanuelle Cambau, Maria Rosaria Capobianchi, Concetta Castilletti, Rosella Centis, Daniela M. Cirillo, Lia D'Ambrosio, Masoud Dara, Giovanni Delogu, Susanna M.R. Esposito, Jose Figueroa, Jon S. Friedland, Benjamin Ho Choon Heng, Giuseppe Ippolito, Tauhidul Islam A.B.M, Mateja Jankovic, Hannah Yejin Kim, Senia Rosales Klintz, Csaba Kodmon, Eleonora Lalle, Yee Sin Leo, Chi-Chiu Leung, Anne-Grete Martson, Mario Melazzini, Saeid Najafi Fard, Pasi Penttinen, Linda Petrone, Elisa Petruccioli, Emanuele Pontali, Laura Saderi, Miguel Santin, Antonio Spanevello, Reinout van Crevel, Martin van den Boom, Marieke J. van der Werf, Dina Visca, Miguel Viveiros, Jean Pierre Zellweger, Alimuddin Zumla, Delia Goletti. Epidemic and pandemic viral infections: impact on tuberculosis and the lung. A consensus by the World Association for Infectious Diseases and Immunological Disorders (WAidid), Global Tuberculosis Network (GTN) and members# of ESCMID Study Group for Mycobacterial Infections (ESGMYC). *ERJ*, in press.
86. Buonsenso D, Iodice F, Sorba J, Biala M, Goletti D. COVID-19 effects on Tuberculosis care in Sierra Leone, *Pulmonology*, in press, PII: S2531-0437(20)30130-6. DOI: <https://doi.org/doi:10.1016/j.pulmoe.2020.05.013>

87. Messina F, Giombini E, Agrati C, Vairo F, Ascoli Bartoli T, Al Moghazi S, Piacentini M, Locatelli F, Kobinger G, Maeurer M, Zumla A, Capobianchi MR, Lauria FN, Ippolito G. COVID-19: viral-host interactome analyzed by network based-approach model to study pathogenesis of SARS-CoV-2 infection. *J Transl Med.* 2020 Jun 10;18(1):233. doi: 10.1186/s12967-020-02405-w. PubMed PMID: 32522207.
88. Tadolini M, Codecasa LR, Garcia-Garcia JM, Blanc FX, Borisov S, Alffenaar JW, Andrejak C, Bachez P, Bart PA, Belilovski E, Cardoso-Landivar J, Centis R, D'Ambrosio L, De Souza-Galvao ML, Dominguez-Castellano A, Dourmane S, Jachym MF, Froissart A, Giacomet V, Goletti D, Grard S, Gualano G, Izadifar A, Le Du D, Royo MM, Mazza-Stalder J, Motta I, Ong CWM, Palmieri F, Riviere F, Rodrigo T, Rossato Silva D, Sanchez-Montalva A, Saporiti M, Scarpellini P, Schlemmer F, Spanevello A, Sumarokova E, Taberner E, Tambyah PA, Tiberi S, Torre A, Visca D, Murguiondo MZ, Sotgiu G, Migliori GB. Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. *Eur Respir J.* 2020 May 26;. doi: 10.1183/13993003.01398-2020.
89. Motta I, Centis R, D'Ambrosio L, Garcia-Garcia JM, Goletti D, Gualano G, Lipani F, Palmieri F, Sanchez-Montalva A, Pontali E, Sotgiu G, Spanevello A, Stochino C, Taberner E, Tadolini M, van den Boom M, Villa S, Visca D, Migliori GB. Tuberculosis, COVID-19 and migrants: preliminary analysis of deaths occurring in 69 patients from two cohorts. *Pulmonology.* 2020 May 14;. doi: 10.1016/j.pulmoe.2020.05.002. [Epub ahead of print] PubMed PMID: 32411943; PubMed Central PMCID: PMC7221402.
90. Petruccioli E, Chiacchio T, Navarra A, Vanini V, Cuzzi G, Cimaglia C, Codecasa LR, Pinnetti C, Riccardi N, Palmieri F, Antinori A, Goletti D. Effect of HIV-infection on QuantiFERON-plus accuracy in patients with active tuberculosis and latent infection. *J Infect.* 2020 May;80(5):536-546. doi: 10.1016/j.jinf.2020.02.009. Epub 2020 Feb 22. PubMed PMID: 32097688.
91. Lubbers R, Sutherland JS, Goletti D, de Paus RA, Dijkstra DJ, van Moorsel CHM, Veltkamp M, Vestjens SMT, Bos WJW, Petrone L, Malherbe ST, Walz G, Gelderman KA, Groeneveld GH, Geluk A, Ottenhoff THM, Joosten SA, Trouw LA. Expression and production of the SERPING1-encoded endogenous complement regulator C1-inhibitor in multiple cohorts of tuberculosis patients. *Mol Immunol.* 2020 Apr;120:187-195. doi: 10.1016/j.molimm.2020.02.006. Epub 2020 Mar 13. PubMed PMID: 32179338.
92. Esmail H, Cobelens F, Goletti D. Transcriptional biomarkers for predicting development of tuberculosis: progress and clinical considerations. *Eur Respir J.* 2020 Mar;55(3). doi: 10.1183/13993003.01957-2019. Print 2020 Mar. PubMed PMID: 31949119; PubMed Central PMCID: PMC7057180.
93. Tiberi S, Migliori GB, Muhwa Chakaya J, Kaesava T, Salem Al Abri S, Wejse C, Goletti D, Kapata N, Sotgiu G, Bomanji J, Zellweger JP, Hasan R, Irfan M, Ahmed I, Pshenichnaya N, Vasilieva I, Yeboah-Manu D, Alffenaar JW, Yeijin Kim H, Centis R, Cirillo DM, Alagna R, D'Ambrosio L, Maeurer M, Cui X, Cao B, Harries AD, Abri SA, Raviglione M, Zumla A, Petersen E, Ippolito G. Cover Editorial- IJID World TB Day 2020 Theme Series. *Int J Infect Dis.* 2020 Mar 4. pii: S1201-9712(20)30120-X. doi: 10.1016/j.ijid.2020.03.001.
94. Al Abri S, Kasaeva T, Migliori GB, Goletti D, Zenner D, Denholm J, Al Maani A, Cirillo DM, Schon T, Lillebaek T, Al-Jardani A, Go UY, Dias HM, Tiberi S, Al Yaqubi F, Khamis FA, Kurup P, Wilson M, Memish Z, Al Maqbali A, Akhtar M, Wejse C, Petersen E. Tools to implement the WHO End TB Strategy: Addressing common challenges in high and low endemic countries. *Int J Infect Dis.* 2020 Feb 27.
95. Petruccioli E, Chiacchio T, Navarra A, Vanini V, Cuzzi G, Cimaglia C, Codecasa LR, Pinnetti C, Riccardi N, Palmieri F, Antinori A, Goletti D. Effect of HIV-infection on QuantiFERON-plus accuracy in patients with active tuberculosis and latent infection. *J Infect.* 2020 Feb 22.
96. Palucci I, Maulucci G, De Maio F, Sali M, Romagnoli A, Petrone L, Fimia GM, Sanguinetti M, Goletti D, De Spirito M, Piacentini M, Delogu G. Inhibition of Transglutaminase 2 as a Potential Host-Directed Therapy Against Mycobacterium tuberculosis. *Front Immunol.* 2020 Jan 24;10:3042.
97. Esmail H, Cobelens F, Goletti D. Transcriptional biomarkers for predicting development of TB: progress and clinical considerations. *Eur Respir J.* 2020
98. Goletti D, Navarra A, Petruccioli E, Cimaglia C, Compagno M, Cuzzi G, De Carli G, Fondaco L, Franzetti F, Giannetti A, Gori A, Lapadula G, Lichtner M, Mastroianni CM, Mazzotta V, Orchi N, Pavone P, Piacentini D, Pirriatore V, Pontali E, Sarmati L, Spolti A, Tacconelli E, Galli M, Antinori A, Calcagno A, Girardi E. Latent tuberculosis infection screening in persons newly-diagnosed with HIV infection in Italy: a multicentre study promoted by the Italian Society of Infectious and Tropical Diseases. *Int J Infect Dis.* 2019 Dec 27. pii:S1201-9712(19)30504-1. doi: 10.1016/j.ijid.2019.12.031. PubMed PMID: 31887456.

99. Petrone L, Albrich WC, Tamarozzi F, Frischknecht M, Gomez-Morales MA, Teggi A, Hoffmann M, Goletti D. Species-specificity preliminary evaluation of an IL-4 based test for the differential diagnosis of human echinococcosis. *Parasite Immunol.* 2019 Dec 29:e12695. doi: 10.1111/pim.12695. [Epub ahead of print] PubMed PMID: 31884696.
100. Zabotti A, Goletti D, Lubrano E, Cantini F. The impact of the interleukin 12/23 inhibitor ustekinumab on the risk of infections in patients with psoriatic arthritis. *Expert Opin Drug Saf.* 2020 Jan;19(1):69-82. doi: 10.1080/14740338.2020.1703946. Epub 2019 Dec 19. PubMed PMID: 31847608.
101. Larsen ES, Joensen UN, Poulsen AM, Goletti D, Johansen IS. Bacillus Calmette-Guerin immunotherapy for bladder cancer: A review of immunological aspects, clinical effects and BCG infections. *APMIS.* 2019 Nov 22. doi: 10.1111/apm.13011. [Epub ahead of print] Review. PubMed PMID: 31755155.
102. Musso M, Mosti S, Gualano G, Mencarini P, Urso R, Ghirga P, Rianda A, Del Nonno F, Goletti D, Palmieri F. Hepatitis C virus infection: a challenge in the complex management of two cases of multidrug-resistant tuberculosis. *BMC Infect Dis.* 2019 Oct 22;19(1):882. doi: 10.1186/s12879-019-4494-1. PubMed PMID: 31640579; PubMed Central PMCID: PMC6806539.
103. Sotgiu G, Goletti D, Matteelli A. Global tuberculosis prevention: should we start from the beginning? *Eur Respir J.* 2019 Sep 12;54(3). pii: 1901394. doi: 10.1183/13993003.01394-2019. Print 2019 Sep. PubMed PMID: 31515266.
104. Sotgiu G, Saderi L, Petruccioli E, Aliberti S, Piana A, Petrone L, Goletti D. QuantiFERON TB Gold Plus for the diagnosis of tuberculosis: a systematic review and meta-analysis. *J Infect.* 2019 Aug 29. pii: S0163-4453(19)30258-0. doi: 10.1016/j.jinf.2019.08.018. [Epub ahead of print] PubMed PMID: 31473271.
105. Alonzi T, Petruccioli E, Vanini V, Fimia GM, Goletti D. Optimization of the autophagy measurement in a human cell line and primary cells by flow cytometry. *Eur J Histochem.* 2019 Jun 26;63(2). doi: 10.4081/ejh.2019.3044. PubMed PMID: 31243942.
106. Palucci I, Battah B, Salustri A, De Maio F, Petrone L, Ciccocanti F, Sali M, Bondet V, Duffy D, Fimia GM, Goletti D, Delogu G. IP-10 contributes to the inhibition of mycobacterial growth in an ex vivo whole blood assay. *Int J Med Microbiol.* 2019 May 22. pii: S1438-4221(19)30097-9. doi:10.1016/j.ijmm.2019.05.005. [Epub ahead of print] PubMed PMID: 31147175
107. Cantini F, Niccoli L, Capone A, Petrone L, Goletti D. Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice. *Expert Opin Drug Saf.* 2019 May 8:1-11.
108. Chiacchio T, Petruccioli E, Vanini V, Cuzzi G, Massafra U, Baldi G, Navarra A, Scrivo R, Mastroianni C, Sauzullo I, Esposito C, Palmieri F, Cantini F, Goletti D. Characterization of QuantiFERON-TB-Plus results in latent tuberculosis infected patients with or without immune-mediated inflammatory diseases. *J Infect.* 2019 Apr 11.
109. Gualano G, Mencarini P, Musso M, Mosti S, Santangelo L, Murachelli S, Cannas A, Di Caro A, Navarra A, Goletti D, Girardi E, Palmieri F. Putting in harm to cure: Drug related adverse events do not affect outcome of patients receiving treatment for multidrug-resistant Tuberculosis. Experience from a tertiary hospital in Italy. *PLoS One.* 2019 Feb 28;14(2):e0212948.
110. Santos VS, Goletti D, Kontogianni K, Adams ER, Molina-Moya B, Dominguez J, Crudu V, Martins-Filho PRS, Ruhwald M, Lawson L, Bimba JS, Garcia-Basteiro AL, Petrone L, Kabeer BS, Reither K, Cuevas LE. Acute phase proteins and IP-10 as triage tests for the diagnosis of tuberculosis: systematic review and meta-analysis. *Clin Microbiol Infect.* 2019 Feb;25(2):169-177.
111. Coluzzi F, Meniconi RL, Caruso D, Rivosecchi F, Petrone L, Goletti D, Ettore GM. Severe chest allodynia as an unusual first presentation of hydatid disease: a case report. *BMC Infect Dis.* 2019 Jan 9;19(1):37. doi: 10.1186/s12879-019-3670-7.
112. Petrone L, Bondet V, Vanini V, Cuzzi G, Palmieri F, Palucci I, Delogu G, Ciccocanti F, Fimia GM, Blauenfeldt T, Ruhwald M, Duffy D, Goletti D. First description of agonist and antagonist IP-10 in urine of patients with active TB. *Int J Infect Dis.* 2019 Jan;78:15-21.
113. De Maio F, Battah B, Palmieri V, Petrone L, Corrente F, Salustri A, Palucci I, Bellesi S, Papi M, Rubino S, Sali M, Goletti D, Sanguinetti M, Manganelli R, De Spirito M, Delogu G. PE\_PGRS3 of *Mycobacterium tuberculosis* is specifically expressed at low phosphate concentration, and its arginine-rich C-terminal domain mediates adhesion and persistence in host tissues when expressed in *Mycobacterium smegmatis*. *Cell Microbiol.* 2018 Dec;20(12):e12952. doi: 10.1111/cmi.12952.
114. Goletti D, Lindestam Arlehamn CS, Scriba TJ, Anthony R, Cirillo DM, Alonzi T, Denking CM, Cobelens F. Can we predict tuberculosis cure? What tools are available? *Eur Respir J.* 2018 Nov

8;52(5). pii: 1801089. doi: 10.1183/13993003.01089-2018. Print 2018 Nov. Review. PubMed PMID: 30361242.

115. De Maio F, Squeglia F, Goletti D, Delogu G. The Mycobacterial HBHA Protein: a Promising Biomarker for Tuberculosis. *Curr Med Chem*. 2018 Oct 29. doi: 10.2174/0929867325666181029165805.
116. Santos VS, Goletti D, Kontogianni K, Adams ER, Molina-Moya B, Dominguez J, Crudu V, Martins-Filho PRS, Ruhwald M, Lawson L, Bimba JS, Garcia-Bastero AL, Petrone L, Kabeer BS, Reither K, Cuevas LE. Acute phase proteins and IP-10 as triage tests for the diagnosis of tuberculosis: a systematic review and meta-analysis. *Clin Microbiol Infect*. 2018 Aug 1.
117. Blauenfeldt T, Petrone L, Del Nonno F, Baiocchini A, Falasca L, Chiacchio T, Bondet V, Vanini V, Palmieri F, Galluccio G, Casrouge A, Eugen-Olsen J, Albert ML, Goletti D, Duffy D, Ruhwald M. Interplay of DDP4 and IP-10 as a Potential Mechanism for Cell Recruitment to Tuberculosis Lesions. *Front Immunol*. 2018 Jul 5;9:1456.
118. Andrade JM, Custodio L, Romagnoli A, Reis CP, Rodrigues MJ, Garcia C, Petruccioli E, Goletti D, Faustino C, Fimia GM, Rijo P. Antitubercular and anti-inflammatory properties screening of natural products from *Plectranthus* species. *Future Med Chem*. 2018 Jun 29.
119. Schinina V, Albarello F, Cristofaro M, Di Stefano F, Fusco N, Cuzzi G, Arend SM, Goletti D, Busi Rizzi E. Diagnostic imaging of hepatic tuberculosis: case series. *Int J Tuberc Lung Dis*. 2018 Jul 1;22(7):779-787.
120. Orlando V, La Manna MP, Goletti D, Palmieri F, Lo Presti E, Joosten SA, La Mendola C, Buccheri S, Ottenhoff THM, Dieli F, Caccamo N. Human CD4 T-Cells With a Naive Phenotype Produce Multiple Cytokines During Mycobacterium Tuberculosis Infection and Correlate With Active Disease. *Front Immunol*. 2018 May 23;9:1119.
121. Goletti D, Petrone L, Ippolito G, Niccoli L, Nannini C, Cantini F. Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs. *Expert Rev Anti Infect Ther*. 2018 Jun 12:1-12.
122. Romagnoli A, Petruccioli E, Palucci I, Camassa S, Carata E, Petrone L, Mariano S, Sali M, Dini L, Girardi E, Delogu G, Goletti D, Fimia GM. Clinical isolates of the modern Mycobacterium tuberculosis lineage 4 evade host defense in human macrophages through eluding IL-1-induced autophagy. *Cell Death Dis*. 2018 May 24;9(6):624.
123. Chiacchio T, Petruccioli E, Vanini V, Cuzzi G, Manna MP, Orlando V, Pinnetti C, Sampaolesi A, Antinori A, Caccamo N, Goletti D. Impact of antiretroviral and tuberculosis therapies on CD4(+) and CD8(+) HIV/M. tuberculosis-specific T-cell in co-infected subjects. *Immunol Lett*. 2018 Apr 7.
124. Goletti D, Montesano C, Mattei M, Migliori GB. Professor Massimo Amicosante, 1968-2017. *Int J Tuberc Lung Dis*. 2018 Feb 1;22(2):236. doi: 10.5588/ijtld.17.0772. PubMed PMID: 29506622.
125. Carvalho I, Goletti D, Manga S, Silva DR, Manissero D, Migliori G. Managing latent tuberculosis infection and tuberculosis in children. *Pulmonology*. 2018 Mar - Apr;24(2):106-114. doi: 10.1016/j.rppnen.2017.10.007. Epub 2018 Mar 2. PubMed PMID: 29502937.
126. Baddley JW, Cantini F, Goletti D, Gomez-Reino JJ, Mylonakis E, San-Juan R, Fernandez-Ruiz M, Torre-Cisneros J. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumour necrosis factor- agents). *Clin Microbiol Infect*. 2018 Feb 6. pii: S1198-743X(18)30030-2. doi: 10.1016/j.cmi.2017.12.025.
127. Goletti D, Lee MR, Wang JY, Walter N, Ottenhoff THM. Update on tuberculosis biomarkers: From correlates of risk, to correlates of active disease and of cure from disease. *Respirology*. 2018 Feb 18. doi: 10.1111/resp.13272.
128. Paolino M, Brindisi M, Vallone A, Butini S, Campiani G, Nannicini C, Giuliani G, Anzini M, Lamponi S, Giorgi G, Sbardella D, Ferraris DM, Marini S, Coletta M, Palucci I, Minerva M, Delogu G, Pepponi I, Goletti D, Cappelli A, Gemma S, Brogi S. Development of Potent Inhibitors of the Mycobacterium tuberculosis Virulence Factor Zmp1 and Evaluation of Their Effect on Mycobacterial Survival inside Macrophages. *ChemMedChem*. 2018 Mar 6;13(5):422-430. doi: 10.1002/cmdc.201700759. Epub 2018 Feb 14. PubMed PMID: 29334428.
129. Parlato S, Chiacchio T, Salerno D, Petrone L, Castiello L, Romagnoli G, Canini I, Goletti D, Gabriele L. Impaired IFN--mediated signal in dendritic cells differentiates active from latent tuberculosis. *PLoS One*. 2018 Jan 10;13(1):e0189477. doi: 10.1371/journal.pone.0189477. eCollection 2018..
130. Palucci I, Matic I, Falasca L, Minerva M, Maulucci G, De Spirito M, Petruccioli E, Goletti D, Rossin F, Piacentini M, Delogu G. Transglutaminase type 2 plays a key role in the pathogenesis of Mycobacterium tuberculosis infection. *J Intern Med*. 2017 Dec 4. doi: 10.1111/joim.12714.

131. Petrone L, Vanini V, Amicosante M, Corpolongo A, Gomez Morales MA, Ludovisi A, Ippolito G, Pozio E, Teggi A, Goletti D. A T-cell diagnostic test for cystic echinococcosis based on Antigen B peptides. *Parasite Immunol.* 2017 Dec;39(12). doi: 10.1111/pim.12499.
132. Amicosante M, D'Ambrosio L, Munoz M, Mello FCQ, Tebruegge M, Chegou NN, Seghrouchni F, Centis R, Goletti D, Bothamley G, Migliori GB; TB Diagnostic Survey Working Group. Current use and acceptability of novel diagnostic tests for active tuberculosis: a worldwide survey. *J Bras Pneumol.* 2017 Sep-Oct;43(5):380-392. doi: 10.1590/S1806-37562017000000219.
133. Kaufmann SHE, Dockrell HM, Drager N, Ho MM, McShane H, Neyrolles O, Ottenhoff THM, Patel B, Roordink D, Spertini F, Stenger S, Thole J, Verreck FAW, Williams A; TBVAC2020 Consortium. TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development. *Front Immunol.* 2017 Oct 4;8:1203. doi: 10.3389/fimmu.2017.01203.
134. Chiacchio T, Delogu G, Vanini V, Cuzzi G, De Maio F, Pinnetti C, Sampaolesi A, Antinori A, Goletti D. Immune characterization of the HBHA-specific response in Mycobacterium tuberculosis-infected patients with or without HIV infection. *PLoS One.* 2017 Aug 24;12(8):e0183846. doi: 10.1371/journal.pone.0183846
135. Jones A, Pitts M, Al Dulayymi JR, Gibbons J, Ramsay A, Goletti D, Gwenin CD, Baird MS. New synthetic lipid antigens for rapid serological diagnosis of tuberculosis. *PLoS One.* 2017 Aug 14;12(8):e0181414.
136. Petruccioli E, Vanini V, Chiacchio T, Cuzzi G, Cirillo DM, Palmieri F, Ippolito G, Goletti D. Analytical evaluation of QuantiFERON- Plus and
137. QuantiFERON- Gold In-tube assays in subjects with or without tuberculosis. *Tuberculosis (Edinb).* 2017 Sep;106:38-43.
138. Scriba TJ, Carpenter C, Carrasco Pro S, Sidney J, Musvosvi M, Rozot V, Seumois G, Rosales SL, Vijayanand P, Goletti D, Makgotlho E, Hanekom W, Hatherill M, Peters B, Sette A, Lindestam Arlehamn CS. Differential Recognition of Mtb-specific Epitopes as a Function of Tuberculosis Disease History. *Am J Respir Crit Care Med.* 2017 Jul 31. doi: 10.1164/rccm.201706-1208OC.
139. Cantini F, Nannini C, Niccoli L, Petrone L, Ippolito G, Goletti D. Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics. *Mediators Inflamm.* 2017;2017:8909834.
140. Benet T, Sanchez Picot V, Messaoudi M, Chou M, Eap T, Wang J, Shen K, Pape JW, Rouzier V, Awasthi S, Pandey N, Bavdekar A, Sanghavi S, Robinson A, Rakoto-Andrianarivelo M, Sylla M, Diallo S, Nymadawa P, Naranbat N, Russomando G, Basualdo W, Komurian-Pradel F, Endtz H, Vanhems P, Paranhos-Baccala G; Global Approach to Biological Research, Infectious diseases and Epidemics in Low-income countries (GABRIEL) Network . Microorganisms Associated With Pneumonia in Children <5 Years of Age in Developing and Emerging Countries: The GABRIEL Pneumonia Multicenter, Prospective, Case-Control Study. *Clin Infect Dis.* 2017
141. Solovic I, Abubakar I, Sotgiu G, Dara M, Goletti D, Duarte R, Aliberti S, de Benedictis FM, Ward B, Teixeira V, Gratziau C, Migliori GB. Standard operating procedures for tuberculosis care. *Eur Respir J.* 2017 Jun 1;49(6).
142. Petruccioli E, Scriba TJ, Petrone L, Hatherill M, Cirillo DM, Joosten SA, Codecasa LR, Ottenhoff TH, Denkinger CM, Goletti D. Long-lasting tuberculous pleurisy. *Eur Respir J.* 2017 May 25;49(5). pii: 1700356.
143. Cantini F, Niccoli L, Nannini C, Cassara E, Kaloudi O, Giulio Favalli E, Becciolini A, Benucci M, Gobbi FL, Guiducci S, Foti R, Mosca M, Goletti D. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. *Semin Arthritis Rheum.* 2017 Mar 22. pii: S0049-0172(17)30062-8.
144. La Manna MP, Orlando V, Dieli F, Di Carlo P, Cascio A, Cuzzi G, Palmieri F, Goletti D, Caccamo N. Quantitative and qualitative profiles of circulating monocytes may help identifying tuberculosis infection and disease stages. *PLoS One.* 2017 Feb 16;12(2):e0171358.
145. Girardi E, Sane Schepisi M, Goletti D, Bates M, Mwaba P, Yeboah-Manu D, Ntoui F, Palmieri F, Maeurer M, Zumla A, Ippolito G. The global dynamics of diabetes and tuberculosis: the impact of migration and policy implications. *Int J Infect Dis.* 2017 Mar;56:45-53.
146. Petruccioli E, Chiacchio T, Pepponi I, Vanini V, Urso R, Cuzzi G, Barcellini L, Palmieri F, Cirillo DM, Ippolito G, Goletti D. Characterization of the CD4 and CD8 T-cell response in the QuantiFERON-TB Gold Plus kit. *Int J Mycobacteriol.* 2016 Dec;5 Suppl 1:S25-S26.
147. Petruccioli E, Vanini V, Chiacchio T, Cirillo DM, Palmieri F, Ippolito G, Goletti D. Modulation of interferon-gamma response to QuantiFERON-TB-plus detected by enzyme-linked immunosorbent assay in patients with active and latent tuberculosis infection. *Int J Mycobacteriol.* 2016 Dec;5 Suppl



1:S143-S144.

148. Chiacchio T, Petruccioli E, Pepponi I, Vanini V, Gualano G, Cirillo D, Palmieri F, Ippolito G, Goletti D. Modulation of CD4 and CD8 response to QuantiFERON-TB Plus in patients with active tuberculosis and latent tuberculosis infection followed over time during treatment. *Int J Mycobacteriol*. 2016 Dec;5 Suppl 1:S141-S142.
149. Matucci A, Cammelli D, Cantini F, Goletti D, Marino V, Milano GM, Scarpa R, Tocci G, Maggi E, Vultaggio A. Influence of anti-TNF immunogenicity on safety in rheumatic disease: a narrative review. *Expert Opin Drug Saf*. 2016 Dec;15(sup1):3-10. PubMed PMID: 27924646.
150. Tocci G, Goletti D, Marino V, Matucci A, Milano GM, Cantini F, Scarpa R. Cardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: a focus on rheumatoid arthritis. *Expert Opin Drug Saf*. 2016 Dec;15(sup1):55-61. PubMed PMID: 27924645.
151. Bonovas S, Minozzi S, Lytras T, Gonzalez-Lorenzo M, Pecoraro V, Colombo S, Polloni I, Moja L, Cinquini M, Marino V, Goletti D, Matucci A, Tocci G, Milano GM, Scarpa R, Cantini F. Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. *Expert Opin Drug Saf*. 2016 Dec;15(sup1):35-54. PubMed PMID: 27924644.
152. Minozzi S, Bonovas S, Lytras T, Pecoraro V, Gonzalez-Lorenzo M, Bastiampillai AJ, Gabrielli EM, Lonati AC, Moja L, Cinquini M, Marino V, Matucci A, Milano GM, Tocci G, Scarpa R, Goletti D, Cantini F. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. *Expert Opin Drug Saf*. 2016 Dec;15(sup1):11-34. PubMed PMID: 27924643.
153. Petruccioli E, Scriba TJ, Petrone L, Hatherill M, Cirillo DM, Joosten SA, Ottenhoff TH, Denkinger CM, Goletti D. Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis. *Eur Respir J*. 2016 Nov 11. pii: ERJ-01012-2016. doi: 10.1183/13993003.01012-2016.
154. Barcellini L, Borroni E, Brown J, Brunetti E, Campisi D, Castellotti PF, Codecasa LR, Cugnata F, Di Serio C, Ferrarese M, Goletti D, Lipman M, Rancoita PM, Russo G, Tadolini M, Vanino E, Cirillo DM. First evaluation of QuantiFERON-TB Gold Plus performance in contact screening. *Eur Respir J*. 2016 Nov;48(5):1411-1419.
155. Petrone L, Cannas A, Vanini V, Cuzzi G, Aloï F, Nsubuga M, Sserunkuma J, Nazziwa RA, Jugheli L, Lukindo T, Girardi E, Antinori A, Pucci L, Reither K, Goletti D. Blood and urine inducible protein 10 as potential markers of disease activity. *Int J Tuberc Lung Dis*. 2016 Nov;20(11):1554-1561.
156. Polverino E, Bothamley GH, Goletti D, Heyckendorf J, Sotgiu G, Aliberti S. The best of respiratory infections from the 2015 European Respiratory Society International Congress. *ERJ Open Res*. 2016 Jul 11;2(3).
157. Petruccioli E, Chiacchio T, Pepponi I, Vanini V, Urso R, Cuzzi G, Barcellini L, Cirillo DM, Palmieri F, Ippolito G, Goletti D. First characterization of the CD4 and CD8 T-cell responses to QuantiFERON-TB Plus. *J Infect*. 2016 Oct 4.
158. Delogu G, Vanini V, Cuzzi G, Chiacchio T, De Maio F, Battah B, Pinnetti C, Sampaolesi A, Antinori A, Goletti D. Lack of response to HBHA in HIV-infected patients with latent tuberculosis infection. *Scand J Immunol*. 2016 Sep 16.
159. Cirillo DM, Barcellini L, Goletti D. Preliminary data on precision of QuantiFERON-TB Plus performance. *Eur Respir J*. 2016 Sep;48(3):955-6.
160. Dara M, Solovic I, Sotgiu G, D'Ambrosio L, Centis R, Tran R, Goletti D, Duarte R, Aliberti S, de Benedictis FM, Bothamley G, Schaberg T, Abubakar I, Teixeira V, Ward B, Gratziau C, Migliori GB. Tuberculosis care among refugees arriving in Europe: a ERS/WHO Europe Region survey of current practices. *Eur Respir J*. 2016
161. Petruccioli E, Navarra A, Petrone L, Vanini V, Cuzzi G, Gualano G, Palmieri F, Girardi E, Goletti D. Use of several immunological markers to model the probability of active tuberculosis. *Diagn Microbiol Infect Dis*. 2016 Jun 14.
162. Goletti D, Petruccioli E, Joosten SA, Ottenhoff TH. Tuberculosis Biomarkers: From Diagnosis to Protection. *Infect Dis Rep*. 2016 Jun 24;8(2):6568.
163. Barcellini L, Borroni E, Brown J, Brunetti E, Campisi D, Castellotti PF, Codecasa LR, Cugnata F, Di Serio C, Ferrarese M, Goletti D, Lipman M, Rancoita PM, Russo G, Tadolini M, Vanino E, Cirillo DM. First evaluation of QuantiFERON-TB Gold Plus performance in contact screening. *Eur Respir J*. 2016 Jul 7.
164. Dara M, Solovic I, Goletti D, Sotgiu G, Centis R, D'Ambrosio L, Ward B, Teixeira V, Gratziau C,

- Migliori GB. Preventing and controlling tuberculosis among refugees in Europe: more is needed. *Eur Respir J*. 2016 Jul;48(1):272-4.
165. Joosten SA, van Meijgaarden KE, Del Nonno F, Baiocchini A, Petrone L, Vanini V, Smits HH, Palmieri F, Goletti D, Ottenhoff TH. Patients with Tuberculosis Have a Dysfunctional Circulating B-Cell Compartment, Which Normalizes following Successful Treatment. *PLoS Pathog*. 2016 Jun 15;12(6):e1005687.
166. Vennarecci G, Manfredelli S, Guglielmo N, Laurenzi A, Goletti D, Ettore GM. Major liver resection for recurrent hydatid cyst of the liver after suboptimal treatment. *Updates Surg*. 2016 Apr 28.
167. Dara M, Solovic I, Sotgiu G, D'Ambrosio L, Centis R, Goletti D, Duarte R, Aliberti S, de Benedictis FM, Bothamley G, Schaberg T, Abubakar I, Ward B, Teixeira V, Gratziau C, Migliori GB. Call for urgent actions to ensure access to early diagnosis and care of tuberculosis among refugees: Statement of the European Respiratory Society and the European Region of the International Union Against Tuberculosis and Lung Disease. *Eur Respir J*. 2016 May;47(5):1345-7.
168. Barcellini L, Borroni E, Brown J, Brunetti E, Codecasa L, Cugnata F, Dal Monte P, Di Serio C, Goletti D, Lombardi G, Lipman M, Rancoita PM, Tadolini M, Cirillo DM. First independent evaluation of QuantiFERON-TB Plus performance. *Eur Respir J*. 2016 Feb 11.
169. Klionsky DJ, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy*. 2016 Jan 2;12(1):1-222. PubMed PMID: 26799652.
170. Boer MC, van Meijgaarden KE, Goletti D, Vanini V, Prins C, Ottenhoff TH, Joosten SA. KLRG1 and PD-1 expression are increased on T-cells following tuberculosis-treatment and identify cells with different proliferative capacities in BCG-vaccinated adults. *Tuberculosis (Edinb)*. 2016 Mar;97:163-71.
171. Cantini F, Niccoli L, Nannini C, Cassara E, Kaloudi O, Giulio Favalli E, Becciolini A, Biggioggero M, Benucci M, Li Gobbi F, Grossi V, Infantino M, Meacci F, Manfredi M, Guiducci S, Bellando-Randone S, Matucci-Cerinic M, Foti R, Di Gangi M, Mosca M, Tani C, Palmieri F, Goletti D; Italian board for the Tailored BIOlogic therapy (ITABIO). Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. *Semin Arthritis Rheum*. 2015 Oct 22. pii: S0049-0172(15)00241-3.
172. Petrone L, Vanini V, Petruccioli E, Ettore GM, Schinina V, Busi Rizzi E, Ludovisi A, Corpolongo A, Ippolito G, Pozio E, Teggi A, Goletti D. Polyfunctional Specific Response to *Echinococcus Granulosus* Associates to the Biological Activity of the Cysts. *PLoS Negl Trop Dis*. 2015 Nov 17;9(11):e0004209.
173. Sali M, Buonsenso D, Goletti D, D'Alfonso P, Zumbo A, Fadda G, Sanguinetti M, Delogu G, Valentini P. Accuracy of QuantiFERON-TB Gold Test for Tuberculosis Diagnosis in Children. *PLoS One*. 2015 Oct 6;10(10):e0138952.
174. Petrone L, Cannas A, Aloï F, Nsubuga M, Sserumkuma J, Nazziwa RA, Jugheli L, Lukindo T, Girardi E, Reither K, Goletti D. Blood or Urine IP-10 Cannot Discriminate between Active Tuberculosis and Respiratory Diseases Different from Tuberculosis in Children. *Biomed Res Int*. 2015;2015:589471.
175. Carpenter C, Sidney J, Kolla R, Nayak K, Tomiyama H, Tomiyama C, Padilla OA, Rozot V, Ahamed SF, Ponte C, Rolla V, Antas PR, Chandele A, Kenneth J, Laxmi S, Makgotlho E, Vanini V, Ippolito G, Kazanova AS, Panteleev AV, Hanekom W, Mayanja-Kizza H, Lewinsohn D, Saito M, McElrath MJ, Boom WH, Goletti D, Gilman R,
176. Lyadova IV, Scriba TJ, Kallas EG, Murali-Krishna K, Sette A, Lindestam Arlehamn CS. A side-by-side comparison of T cell reactivity to fifty-nine *Mycobacterium tuberculosis* antigens in diverse populations from five continents. *Tuberculosis (Edinb)*. 2015 Aug 1.
177. Petruccioli E, Petrone L, Vanini V, Cuzzi G, Navarra A, Gualano G, Palmieri F, Girardi E, Goletti D. Assessment of CD27 expression as a tool for active and latent tuberculosis diagnosis. *J Infect*. 2015 Aug 5.
178. Spinicci M, Mencarini J, Goletti D, Mantella A, Della Malva N, Bartoloni A, Bartalesi F. Discordance between the QuantiFERON-TB Gold In-Tube and Tuberculin Skin Test: need for a further step? *Eur Respir J*. 2015 Jul 23. pii: ERJ-00403-2015. doi: 10.1183/13993003.00403-2015.
179. Guggino G, Orlando V, Cutrera S, La Manna MP, Di Liberto D, Vanini V, Petruccioli E, Dieli F, Goletti D, Caccamo N. Granzyme A as a potential biomarker of *Mycobacterium tuberculosis* infection and disease. *Immunol Lett*. 2015 Aug;166(2):87-91. doi: 10.1016/j.imlet.2015.05.019.
180. El Daker S, Sacchi A, Tempestilli M, Carducci C, Goletti D, Vanini V, Colizzi V, Lauria FN, Martini F, Martino A. Granulocytic Myeloid Derived Suppressor Cells Expansion during Active Pulmonary Tuberculosis Is Associated with High Nitric Oxide Plasma Level. *PLoS One*. 2015 Apr 16;10(4):e0123772

181. Xia H, Wang X, Li F, Longuet C, Vernet G, Goletti D, Zhao Y, Lagrange PH. Diagnostic Values of the QuantiFERON-TB Gold In-Tube Assay Carried out in China for Diagnosing Pulmonary Tuberculosis. *PLoS One*. 2015 Apr 13;10(4):e0121021.
182. Lonroth K, Migliori GB, Abubakar I, D'Ambrosio L, de Vries G, Diel R, Douglas P, Falzon D, Gaudreau MA, Goletti D, Gonzalez Ochoa ER, LoBue P, Matteelli A, Njoo H, Solovic I, Story A, Tayeb T, van der Werf MJ, Weil D, Zellweger JP, Abdel Aziz M, Al Lawati MR, Aliberti S, Arrazola de Onate W, Barreira D, Bhatia V, Blasi F, Bloom A, Bruchfeld J, Castelli F, Centis R, Chemtob D, Cirillo DM, Colorado A, Dadu A, Dahle UR, De Paoli L, Dias HM, Duarte R, Fattorini L, Gaga M, Getahun H, Glaziou P, Gogvadze L, Del Granado M, Haas W, Jarvinen A, Kwon GY, Mosca D, Nahid P, Nishikiori N, Noguer I, O'Donnell J, Pace-Asciak A, Pompa MG, Popescu GG, Robalo Cordeiro C, Ronning K, Ruhwald M, Sculier JP, Simunovic A, Smith-Palmer A, Sotgiu G, Sulis G, A Torres-Duque C, Umeki K, Uplekar M, van Weezenbeek C, Vasankari T, Vitillo RJ, Voniatis C, Wanlin M, Raviglione MC. Towards tuberculosis elimination: an action framework for low-incidence countries. *Eur Respir J*. 2015 Mar 18.
183. Zellweger JP, Sotgiu G, Block M, Dore S, Altet N, Blunski R, Bogyi M, Bothamley G, Bothe C, Codecasa L, Costa P, Dominguez J, Duarte R, Floe A, Fresard I, Garcia-Garcia JM, Goletti D, Halm P, Hellwig D, Henninger E, Heykes-Uden H, Horn L, Kruczak K, Latorre I, Pache G, Rath H, Ringshausen FC, Seminario Ruiz A, Solovic I, de Souza-Galvao ML, Widmer U, Witte P, Lange C; TBNET. Risk Assessment of Tuberculosis in Contacts by Interferon- Release Assays (IGRAs). A TBNET Study. *Am J Respir Crit Care Med*. 2015 Mar 12.
184. Sane Schepisi M, Parracino MP, Mammone A, Bellagamba R, Pinnetti C, Cicalini S, Sampaolesi A, Ammassari A, Goletti D, Girardi E. Immune Status and Serial QuantiFERON-TB Gold In-Tube Screening for Latent Mycobacterium tuberculosis Infection Among HIV-Infected Persons in a Country With a Low Tuberculosis Incidence. *J Infect Dis*. 2015 Jan 26.
185. Cantini F, Nannini C, Niccoli L, Iannone F, Delogu G, Garlaschi G, Sanduzzi A, Matucci A, Prignano F, Conversano M, Goletti D; on behalf of SAFEBIO (Italian multidisciplinary task force for screening of tuberculosis before and during biologic therapy). Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. *Autoimmun Rev*. 2015 Jan 21. pii: S1568-9972(15)00026-9.
186. Petrone L, Vanini V, Petruccioli E, Ettorre GM, Busi Rizzi E, Schinina V, Girardi E, Ludovisi A, Gomez-Morales MA, Pozio E, Teggi A, Goletti D. IL-4 specific-response in whole blood associates with human Cystic Echinococcosis and cyst activity. *J Infect*. 2014 Oct 22.
187. Rozot V, Patrizia A, Vigano S, Mazza-Stalder J, Idrizi E, Day CL, Perreau M, Lazor-Blanchet C, Ohmiti K, Goletti D, Bart PA, Hanekom W, Scriba TJ, Nicod L, Pantaleo G, Harari A. Combined Use of Mycobacterium tuberculosis-Specific CD4 and CD8 T-Cell Responses Is a Powerful Diagnostic Tool of Active Tuberculosis. *Clin Infect Dis*. 2014 Oct 31. pii: ciu795.
188. De Visser V, Sotgiu G, Lange C, Aabye MG, Bakker M, Bartalesi F, Brat K, Chee CB, Dheda K, Dominguez J, Eyuboglu F, Ghanem M, Goletti D, Dilektasli AG, Guglielmetti L, Koh WJ, Latorre I, Losi M, Polanova M, Ravn P, Ringshausen FC, Rumetshofer R, de Souza-Galvao ML, Thijsen S, Bothamley G, Bossink A; for the TBNET. False-negative interferon- release assay results in active tuberculosis: a TBNET study. *Eur Respir J*. 2014 Oct 30.
189. Sester M, van Leth F, Bruchfeld J, Bumbacea D, Cirillo DM, Dilektasli AG, Dominguez J, Duarte R, Ernst M, Eyuboglu FO, Gerogianni I, Girardi E, Goletti D, Janssens JP, Julander I, Lange B, Latorre I, Losi M, Markova R, Matteelli A, Milburn H, Ravn P, Scholman T, Soccacal PM, Straub M, Wagner D, Wolf T, Yalcin A, Lange C; TBNET. Risk Assessment of Tuberculosis in Immunocompromised Patients. A TBNET Study. *Am J Respir Crit Care Med*. 2014 Nov 15;190(10):1168-76.
190. Cantini F, Boccia S, Goletti D, Iannone F, Leoncini E, Panic N, Prignano F, Gaeta GB. HBV Reactivation in Patients Treated with Antitumor Necrosis Factor-Alpha (TNF-) Agents for Rheumatic and Dermatologic Conditions: A Systematic Review and Meta-Analysis. *Int J Rheumatol*. 2014;2014:926836.
191. Chiacchio T, Petruccioli E, Vanini V, Cuzzi G, Pinnetti C, Sampaolesi A, Antinori A, Girardi E, Goletti D. Polyfunctional T-cells and effector memory phenotype are associated with active TB in HIV-infected patients. *J Infect*. 2014 Dec;69(6):533-45.
192. Lagrange PH, Thangaraj SK, Dayal R, Deshpande A, Ganguly NK, Girardi E, Joshi B, Katoch K, Katoch VM, Kumar M, Lakshmi V, Leportier M, Longuet C, Malladi SV, Mukerjee D, Nair D, Raja A, Raman B, Rodrigues C, Sharma P, Singh A, Singh S, Sodha A, Kabeer BS, Vernet G, Goletti D. A toolbox for tuberculosis (TB) diagnosis: an Indian multi-centric study (2006-2008); evaluation of serological assays based on PGL-Tb1 and ESAT-6/CFP10 antigens for TB diagnosis. *PLoS One*.

2014 May 5;9(5):e96367.

193. Cantini F, Boccia S, Goletti D, Iannone F, Leoncini E, Panic N, Prignano F, Gaeta GB. HBV Reactivation in Patients Treated with Antitumor Necrosis Factor-Alpha (TNF-) Agents for Rheumatic and Dermatologic Conditions: A Systematic Review and Meta-Analysis. *Int J Rheumatol*. 2014
194. Lagrange PH, Thangaraj SK, Dayal R, Deshpande A, Ganguly NK, Girardi E, Joshi B, Katoch K, Katoch VM, Kumar M, Lakshmi V, Leportier M, Longuet C, Malladi SV, Mukerjee D, Nair D, Raja A, Raman B, Rodrigues C, Sharma P, Singh A, Singh S, Sodha A, Kabeer BS, Vernet G, Goletti D. A Toolbox for Tuberculosis (TB) Diagnosis: An Indian Multi-Centric Study (2006-2008); Evaluation of Serological Assays Based on PGL-Tb1 and ESAT-6/CFP10 Antigens for TB Diagnosis. *PLoS One*. 2014 May 5;9(5):e96367.
195. Cantini F, Prignano F, Goletti D. Restarting biologics and management of patients with flares of inflammatory rheumatic disorders or psoriasis during active tuberculosis treatment. *J Rheumatol Suppl*. 2014 May;91:78-82.
196. Cantini F, Niccoli L, Goletti D. Tuberculosis Risk in Patients Treated with Non-Anti-Tumor Necrosis Factor- (TNF-) Targeted Biologics and Recently Licensed TNF- Inhibitors: Data from Clinical Trials and National Registries. *J Rheumatol Suppl*. 2014 May;91:56-64.
197. Cantini F, Niccoli L, Goletti D. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance. *J Rheumatol Suppl*. 2014 May;91:47-55.
198. Goletti D, Sanduzzi A, Delogu G. Performance of the Tuberculin Skin Test and Interferon-Release Assays: An Update on the Accuracy, Cutoff Stratification, and New Potential Immune-based Approaches. *J Rheumatol Suppl*. 2014 May;91:24-31.
199. Delogu G, Goletti D. The spectrum of tuberculosis infection: new perspectives in the era of biologics. *J Rheumatol Suppl*. 2014 May;91:11-6.
200. Cantini F, Goletti D. Biologics and tuberculosis risk: the rise and fall of an old disease and its new resurgence. *J Rheumatol Suppl*. 2014 May;91:1-3..
201. Lange C, Abubakar I, Alffenaar JW, Bothamley G, Caminero JA, Carvalho AC, Chang KC, Codecasa L, Correia A, Crudu V, Davies P, Dedicoat M, Drobniewski F, Duarte R, Ehlers C, Erkens C, Goletti D, Gunther G, Ibraim E, Kampmann B, Kuksa L, de Lange W, van Leth F, van Lunzen J, Matteelli A, Menzies D, Monedero I, Richter E, Rusch-Gerdes S, Sandgren A, Scardigli A, Skrahina A, Tortoli E, Volchenkov G, Wagner D, van der Werf MJ, Williams B, Yew WW, Zellweger JP, Cirillo DM; for the TBNET. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. *Eur Respir J*. 2014 Mar 23.
202. Petrone L, Chiacchio T, Vanini V, Petruccioli E, Cuzzi G, Di Giacomo C, Pucci L, Montalbano M, Lionetti R, Testa A, Lapa D, Navarra A, Visco-Comandini U, Goletti D. High urine IP-10 levels associate with chronic HCV infection. *J Infect*. 2014 Feb 26. pii: S0163-4453(14)00044-9. doi: 10.1016/j.jinf.2014.02.008.
203. Miotto P, Mwangoka G, Valente IC, Norbis L, Sotgiu G, Bosu R, Ambrosi A, Codecasa LR, Goletti D, Matteelli A, Ntinginya EN, Aloï F, Heinrich N, Reither K, Cirillo DM. miRNA Signatures in Sera of Patients with Active Pulmonary Tuberculosis. *PLoS One*. 2013 Nov 21;8(11):e80149.
204. Petrone L, Cuzzi G, Colace L, Ettore GM, Busi-Rizzi E, Schinina V, Pucillo L, Angeletti C, Pane S, Di Caro A, Bordi E, Girardi E, Pozio E, Corpolongo A, Teggi A, Brunetti E, Goletti D. Cystic echinococcosis in a single tertiary care center in rome, Italy. *Biomed Res Int*. 2013;2013:978146.
205. Dorhoi A, Iannaccone M, Farinacci M, Fae KC, Schreiber J, Moura-Alves P, Nouailles G, Mollenkopf HJ, Oberbeck-Muller D, Jorg S, Heinemann E, Hahnke K, Lowe D, Del Nonno F, Goletti D, Capparelli R, Kaufmann SH. MicroRNA-223 controls susceptibility to tuberculosis by regulating lung neutrophil recruitment. *J Clin Invest*. 2013 Oct 1.
206. Lagrange PH, Thangaraj SK, Dayal R, Deshpande A, Ganguly NK, Girardi E, Joshi B, Katoch K, Katoch VM, Kumar M, Lakshmi V, Leportier M, Longuet C, Malladi SV, Mukerjee D, Nair D, Raja A, Raman B, Rodrigues C, Sharma P, Singh A, Singh S, Sodha A, Kabeer BS, Vernet G, Goletti D. A Toolbox for Tuberculosis (TB) Diagnosis: An Indian Multicentric Study (2006-2008). Evaluation of QuantiFERON-TB Gold in Tube for TB Diagnosis. *PLoS One*. 2013 Sep 6;8(9):e73579.
207. Petruccioli E, Petrone L, Vanini V, Sampaolesi A, Gualano G, Girardi E, Palmieri F, Goletti D. IFN/TNF specific-cells and effector memory phenotype associate with active tuberculosis. *J Infect*. 2013 Feb 24. doi:pii: S0163-4453(13)00028-5. 10.1016/j.jinf.2013.02.004.
208. Rozot V, Vigano S, Mazza-Stalder J, Idrizi E, Day CL, Perreau M, Lazor-Blanchet C, Petruccioli E, Hanekom W, Goletti D, Bart PA, Nicod L, Pantaleo G, Harari A. Mycobacterium tuberculosis-specific CD8(+) T cells are functionally and phenotypically different between latent infection and active disease. *Eur J Immunol*. 2013 Mar 4. doi: 10.1002/eji.201243262.

209. Goletti D, Petruccioli E, Romagnoli A, Piacentini M, Fimia GM. Autophagy in Mycobacterium tuberculosis infection: A passepertout to flush the intruder out? *Cytokine Growth Factor Rev.* 2013 Feb 7. doi:pil: S1359-6101(13)00003-8. 10.1016/j.cytogfr.2013.01.002. [Epub ahead of print] PubMed PMID: 23395260.
210. Podlekareva DN, Grint D, Post FA, Mocroft A, Panteleev AM, Miller RF, Miro JM, Bruyand M, Furrer H, Riektina V, Girardi E, Losso MH, Cayla JA, Malashenkov EA, Obel N, Skrahina AM, Lundgren JD, Kirk O; HIV-TB Study Group. Health care indexscore and risk of death following tuberculosis diagnosis in HIV-positivepatients. *Int J Tuberc Lung Dis.* 2013 Feb;17(2):198-206. doi: 10.5588/ijtld.12.0224. PubMed PMID: 23317955.
211. Giehl C, Lange C, Duarte R, Bothamley G, Gerlach C, Cirillo DM, Wagner D, Kampmann B, Goletti D, Juers T and Sester M. TBNET - COLLABORATIVE RESEARCH ON TUBERCULOSIS IN EUROPE. *European Journal of Microbiology and Immunology* 2012. 4, pp. 264-274. DOI: 10.1556/EuJMI.2.2012.4.4
212. Bartalesi F, Goletti D, Spinicci M, Cavallo A, Attala L, Mencarini J, Fiori G, Li Gobbi F, Mantella A, Benucci M, Prignano F, Pimpinelli N, Matucci Cerinic M, Girardi E, Bartoloni A. Serial QuantiFERON TB-Gold in-tube testing during LTBI therapy in candidates for TNFi treatment. *J Infect.* 2012 Oct 24. doi:pil: S0163-4453(12)00303-9. 10.1016/j.jinf.2012.10.017.
213. Lagrange PH, Thangaraj SK, Dayal R, Despande A, Ganguly NK, Girardi E, Joshi B, Katoch K, Katoch VM, Kumar M, Lakshmi V, Leportier M, Longuet C, Malladi SV, Mukerjee D, Nair D, Raja A, Raman B, Rodrigues C, Sharma P, Singh A, Singh S, Sodha A, Kabeer BS, Vernet G, Goletti D. A toolbox for tuberculosis diagnosis: an
214. Indian multicentric study (2006-2008): microbiological results. *PLoS One.* 2012;7(8):e43739. Epub 2012 Aug 24.
215. Romagnoli A, Etna MP, Giacomini E, Pardini M, Remoli ME, Corazzari M, Falasca L, Goletti D, Gafa V, Simeone R, Delogu G, Piacentini M, Brosch R, Fimia GM, Coccia EM. ESX-1 dependent impairment of autophagic flux by Mycobacteriumtuberculosis in human dendritic cells. *Autophagy.* 2012 Sep 1;8(9):1357-70.
216. Greco E, Quintiliani G, Santucci MB, Serafino A, Ciccaglione AR, Marcantonio C, Papi M, Maulucci G, Delogu G, Martino A, Goletti D, Sarmati L, Andreoni M, Altieri A, Alma M, Caccamo N, Di Liberto D, De Spirito M, Savage ND, Nisini R, Dieli F, Ottenhoff TH, Fraziano M. Janus-faced liposomes enhance antimicrobial innate immune response in Mycobacterium tuberculosis infection. *Proc Natl Acad Sci U S A.* 2012 May 22;109(21):E1360-8.
217. Bumbacea D, Arend SM, Eyuboglu F, Fishman JA, Goletti D, Ison MG, Jones CE, Kampmann B, Kotton CN, Lange C, Ljungman P, Milburn H, Morris MI, Muller E, Munoz P, Nellore A, Rieder HL, Sester U, Theodoropoulos N, Wagner D, Sester M. The risk of tuberculosis in transplant candidates and recipients: A TBNET consensus statement. *Eur Respir J.* 2012 Apr 10.
218. Goletti D, Sester M. Screening for latent infection with Mycobacterium tuberculosis: a plea for targeted testing in low endemic regions. *Expert Rev Mol Diagn.* 2012 Apr;12(3):231-4.
219. Vanini V, Petruccioli E, Gioia C, Cuzzi G, Orchi N, Rianda A, Alba L, Giancola ML, Conte A, Schinina V, Busi Rizzi E, Girardi E, Goletti D. IP-10 is an additional marker for tuberculosis (TB) detection in HIV-infected persons in a low-TB endemic country. *J Infect.* 2012 Jul;65(1):49-59.
220. Petruccioli E, Romagnoli A, Corazzari M, Coccia EM, Butera O, Delogu G, Piacentini M, Girardi E, Fimia GM, Goletti D. Specific T cells restore the autophagic flux inhibited by Mycobacterium tuberculosis in human primary macrophages. *J Infect Dis.* 2012 May;205(9):1425-35.
221. Laurenti P, Bruno S, Quaranta G, La Torre G, Cairo AG, Nardella P, Delogu G, Fadda G, Pirronti T, Geraci S, Pelargonio S, Lauria FN, Goletti D, Ricciardi G. Tuberculosis in sheltered homeless population of rome: an integrated model of recruitment for risk management. *Scientific World Journal.* 2012;2012:396302.
222. Cingolani A, Cozzi Lepri A, Castagna A, Goletti D, De Luca A, Scarpellini P, Fanti I, Antinori A, d'Arminio Monforte A, Girardi E. Impaired CD4 T-cell count response to combined antiretroviral therapy in antiretroviral-naive HIV-infected patients presenting with tuberculosis as AIDS-defining condition. *Clin Infect Dis.* 2012 Mar;54(6):853-61.
223. Chiacchio T, Petruccioli E, Vanini V, Butera O, Cuzzi G, Petrone L, Matteucci G, Lauria FN, Franken KL, Girardi E, Ottenhoff TH, Goletti D. Higher Frequency of T-Cell Response to M. tuberculosis Latency Antigen Rv2628 at the Site of Active Tuberculosis Disease than in Peripheral Blood. *PLoS One.* 2011;6(11):e27539.
224. Diel R, Goletti D, Lange C, Manissero D. Interferon- release assays for the diagnosis of latent Mycobacterium tuberculosis infection. *Eur Respir J.* 2011 Nov;38(5):1238-9.



225. Borgia P, Cambieri A, Chini F, Coltella L, Delogu G, Di Rosa E, Fadda G, Giorgi Rossi P, Girardi E, Goletti D, Guasticchi G, Morrone A, Pezzotti P, Romagnoli C, Sacerdote M, Russo C, Villani A, Zarelli L. Suspected transmission of tuberculosis in a maternity ward from a smear-positive nurse: preliminary results of clinical evaluations and testing of neonates potentially exposed, Rome, Italy, 1 January to 28 July 2011. *Euro Surveill.* 2011 Oct 6;16(40).
226. Busi Rizzi E, Schinina V, Cristofaro M, Goletti D, Palmieri F, Bevilacqua N, Lauria FN, Girardi E, Bibbolino C. Detection of Pulmonary tuberculosis: comparing MR imaging with HRCT. *BMC Infect Dis.* 2011 Sep 16;11:243.
227. Syed Ahamed Kabeer B, Raja A, Raman B, Thangaraj S, Leportier M, Ippolito G, Girardi E, Lagrange PH, Goletti D. IP-10 response to RD1 antigens might be a useful biomarker for monitoring tuberculosis therapy. *BMC Infect Dis.* 2011 May 19;11(1):135.
228. Delogu G, Chiacchio T, Vanini V, Butera O, Cuzzi G, Bua , Moliccotti P , Zanetti S, Lauria FN, Grisetti S, Magnavita N, Fadda G, Girardi E, Goletti D. Methylated HBHA Produced in *M. smegmatis* Discriminates between Active and Non-Active Tuberculosis Disease among RD1-Responders. *PLoS ONE* 6(3): e18315, 2011.
229. Ruhwald M, Dominguez J, Latorre I, Losi M, Richeldi L, Pasticcini MB, Mazzolla R, Goletti D, Butera O, Bruchfeld J, Gaines H, Gerogianni I, Tuuminen T, Ferrara G, Eugen-Olsen J, Ravn P; on behalf of TBNET. A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with *M. tuberculosis*. *Tuberculosis*: 2011 May;91(3):260-267.
230. Cannas A, Calvo L, Chiacchio T, Cuzzi G, Vanini V, Lauria FN, Pucci L, Girardi E, Goletti D. IP-10 detection in urine is associated with lung diseases. *BMC Infect Dis.* 2010 Nov 22;10:333
231. Diel R, Goletti D, Ferrara G, Bothamley G, Cirillo D, Kampmann B, Lange C, Losi M, Markova R, Migliori GB, Nienhaus A, Ruhwald M, Wagner D, Zellweger JP, Huitric E, Sandgren A, Manissero D. Interferon- $\gamma$  release assays for the diagnosis of latent *Mycobacterium tuberculosis* infection: a systematic review and meta-analysis. *Eur Respir J.* 2011 Jan;37(1):88-99.
232. Girardi E, Goletti D. Do IFN- $\gamma$  release assays predict the risk of TB? New evidence from a study on patients with silicosis. *Expert Rev Anti Infect Ther* 2010 Oct;8(10):1105-8.
233. Goletti D, Raja A, Syed Ahamed Kabeer B, Rodrigues C, Sodha A, Carrara S, Vernet G, Longuet C, Ippolito G, Thangaraj S, Leportier M, Girardi E, Lagrange PH. Is IP-10 an accurate marker for detecting *M. tuberculosis*-specific response in HIV-infected persons? *PLoS One.* 2010 Sep 7;5(9):e12577.
234. Lange C, Bossink A, Eberhardt R, Goletti D, Jafari C, Latorre I, Kirsten D, Losi M, Migliori GB, Sotgiu G. Bronchoalveolar lavage immunodiagnosis for tuberculosis suspects in Europe and Africa. *Thorax.* 2010 Sep;65(9):842; author reply 842-3.
235. Sotgiu G, Centis R, D'ambrosio L, De Lorenzo S, D'arcy Richardson M, Lange C, Manissero D, Migliori GB; TBNET MDR-TB project. Development of a standardized tool to survey MDR-/XDR-TB case management in Europe. *Eur Respir J.* 2010 Jul;36(1):208-11. Multicenter study.
236. Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, Milburn HJ, Kampmann B, Hellmich B, Groves R, Schreiber S, Wallis RS, Sotgiu G, Scholvinck EH, Goletti D, Zellweger JP, Diel R, Carmona L, Bartalesi F, Ravn P, Bossink A, Duarte R, Erkens C, Clark J, Migliori GB, Lange C. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. *Eur Respir J.* 2010 Nov;36(5):1185-206.
237. Goletti D, Raja A, Ahamed Kabeer BS, Rodrigues C, Sodha A, Butera O, Carrara S, Vernet G, Longuet C, Ippolito G, Thangaraj S, Leportier M, Girardi E, Lagrange PH. IFN $\gamma$ , but not IP10, MCP2 or IL2 response to RD1 selected peptides associates to active tuberculosis. *J Infect.* 2010 May 11.
238. Butera O, Chiacchio T, Carrara S, Casetti R, Vanini V, Meraviglia S, Guggino G, Dieli F, Vecchi M, Lauria FN, Marruchella A, Laurenti P, Singh M, Caccamo N, Girardi E, Goletti D. New tools for detecting latent tuberculosis infection: evaluation of RD1-specific long-term response. *BMC Infect Dis.* 2009 Nov 21;9:182.
239. Goletti D, Butera O, Vanini V, Lauria FN, Lange C, Franken KL, Angeletti C, Ottenhoff TH, Girardi E. Response to Rv2628 latency antigen associates with cured tuberculosis and remote infection. *Eur Respir J.* 2009 Nov 19.
240. Podlekareva DN, Mocroft A, Post FA, Riekstina V, Miro JM, Furrer H, Bruyand M, Panteleev AM, Rakhmanova AG, Girardi E, Losso MH, Toibaro JJ, Cayla J, Miller RF, Obel N, Skrahina A, Chentsova N, Lundgren JD, Kirk O; HIV/TB Study Writing Group. Mortality from HIV and TB

- coinfections is higher in Eastern Europe than in Western Europe and Argentina. *AIDS*. 2009 Nov 27;23(18):2485-95. Multicenter study.
243. Biselli R, Mariotti S, Sargentini V, Sauzullo I, Lastilla M, Mengoni F, Vanini V, Girardi E, Goletti D, D'Amelio R, Nisini R. Detection of IL-2 in addition to IFN-gamma discriminates active tuberculosis patients, latently infected individuals and controls. *Clin Microbiol Infect*. 2010 Aug;16(8):1282-4.
244. Girardi E, Angeletti C, Puro V, Sorrentino R, Magnavita N, Vincenti D, Carrara S, Butera O, Ciufoli AM, Squarcione S, Ippolito G, Goletti D. Estimating diagnostic accuracy of tests for latent tuberculosis infection without a gold standard among healthcare workers. *Euro Surveill*. 2009 Oct 29;14(43).
245. Leidl L, Mayanja-Kizza H, Sotgiu G, Baseke J, Ernst M, Hirsch C, Goletti D, Toossi Z, Lange C. Relationship of immunodiagnostic assays for tuberculosis and numbers of circulating CD4+ T-cells in HIV-infection. *Eur Respir J*. 2010 Mar;35(3):619-26.
246. Jafari C, Thijsen S, Sotgiu G, Goletti D, Benitez JA, Losi M, Eberhardt R, Kirsten D, Kalsdorf B, Bossink A, Latorre I, Migliori GB, Strassburg A, Winteroll S, Greinert U, Richeldi L, Ernst M, Lange C; Tuberculosis Network European Trialsgroup. Bronchoalveolar lavage enzyme-linked immunospot for a rapid diagnosis of tuberculosis: a Tuberculosis Network European Trialsgroup study. *Am J Respir Crit Care Med*. 2009 Oct 1;180(7):666-73.
247. Sargentini V, Mariotti S, Carrara S, Gagliardi MC, Teloni R, Goletti D, Nisini R. Cytometric detection of antigen-specific IFN-gamma/IL-2 secreting cells in the diagnosis of tuberculosis. *BMC Infect Dis*. 2009 Jun 23;9:99.
248. Chiacchio T, Casetti R, Butera O, Vanini V, Carrara S, Girardi E, Di Mitri D, Battistini L, Martini F, Borsellino G, Goletti D. Characterization of regulatory T cells identified as CD4(+)CD25(high)CD39(+) in patients with active tuberculosis. *Clin Exp Immunol*. 2009 Jun;156(3):463-70.
249. Mack U, Migliori GB, Sester M, Rieder HL, Ehlers S, Goletti D, Bossink A, Magdorf K, Holscher C, Kampmann B, Arend SM, Detjen A, Bothamley G, Zellweger JP, Milburn H, Diel R, Ravn P, Cobelens F, Cardona PJ, Kan B, Solovic I, Duarte R, Cirillo DM; C. Lange; TBNET. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. *Eur Respir J*. 2009 May;33(5):956-73.
250. Bartalesi F, Vicidomini S, Goletti D, Fiorelli C, Fiori G, Melchiorre D, Tortoli E, Mantella A, Benucci M, Girardi E, Cerinic MM, Bartoloni A. QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection
251. screening in autoimmune diseases. *Eur Respir J*. 2009 Mar;33(3):586-93. Epub 2008
252. Casetti R, Martino A, Sacchi A, Agrati C, Goletti D, Martini F. Do human gammadelta T cells respond to M tuberculosis protein antigens? *Blood*. 2008 Dec 1;112(12):4776-7; author reply 4777.
253. Goletti D and GB Migliori. Respiratory Society. Expert Reviews in Respiratory research, 2008 Dec 1;2(6):707-711.
254. Casetti R, Martino A, Sacchi A, Agrati C, Goletti D, Martini F. Do human gammadelta T cells respond to M tuberculosis protein antigens? *Blood*. 2008 Dec 1;112(12):4776-7.
255. Goletti D, Stefania C, Butera O, Amicosante M, Ernst M, Sauzullo I, Vullo V, Cirillo D, Borroni E, Markova R, Drenska R, Dominguez J, Latorre I, Angeletti C, Navarra A, Petrosillo N, Lauria FN, Ippolito G, Migliori GB, Lange C, Girardi E. Accuracy of immunodiagnostic tests for active tuberculosis using single and combined results: a multicenter TBNET-Study. *PLoS ONE*. 2008;3(10):e3417.
256. Cannas A, Goletti D, Girardi E, Chiacchio T, Calvo L, Cuzzi G, Piacentini M, Melkonyan H, Umansky SR, Lauria FN, Ippolito G, Tomei LD. Mycobacterium tuberculosis DNA detection in soluble fraction of urine from pulmonary tuberculosis patients. *Int J Tuberc Lung Dis*. 2008; 12:146-51
257. Goletti D, Carrara S, Mayanja-Kizza H, Baseke J, Mugerwa MA, Girardi E, Toossi Z. Response to M. tuberculosis selected RD1 peptides in Ugandan HIV-infected patients with smear positive pulmonary tuberculosis: a pilot study. *BMC Infectious Diseases* 2008; 8:11
258. Goletti D, Carrara s, Vincenti D, Girardi E. T cell responses to commercial M. tuberculosis-specific antigens in HIV-infected patients. *Clin Inf Dis* 2007; 45: 1652-54.
259. Palazzo R, Spensieri F, Massari M, Fedele G, Frasca L, Carrara S, Goletti D, Ausiello CM. In-house bulk and single cell antigen-specific whole blood Interferon-gamma assays for surveillance of M. tuberculosis infection. *Clin Vaccine Immunol*, 2007; 15:327-337.
260. Vincenti D, Carrara S, Butera O, Bizzoni F, Casetti R, Girardi E, Goletti D. Response to region of difference 1 (RD1) epitopes in human immunodeficiency virus (HIV)-infected individuals enrolled with suspected active tuberculosis: a pilot study. *Clin Exp Immunol*. 2007;150(1):91-8.

261. Girardi E, Loffredo M, Alessandrini A, Anzidei G, Goletti D. A two-step approach for screening contacts of active tuberculosis. *Infection*. 2007; 35(2):122-3.
262. Goletti D, Parracino MP, Butera O, Bizzoni F, Casetti R, Dainotto D, Anzidei G, Nisii C, Ippolito G, Poccia F, Girardi E. Isoniazid prophylaxis differently modulates T-cell responses to RD1-epitopes in contacts recently exposed to *Mycobacterium tuberculosis*: a pilot study. *Respir Res* 2007;8:5.
263. Girardi E, Goletti D, Ippolito G. Should individuals who are tuberculin skin test negative and positive to RD1-IFN-gamma assay receive preventive therapy? *Am J Respir Crit Care Med*. 2007 Jan 15;175(2):198-199.
264. Goletti D, Macchia I, Leone P, Pace M, Sernicola L, Pavone-Cossut MR, Maggiorella MT, Cafaro A, Ensoli B, Titti F. Innate anti-viral immunity is associated with the protection elicited by the simian immunodeficiency virus (SIV) live attenuated virus vaccine in cynomolgus monkeys. *Med Sci Monit*. 2006 Oct;12(10):BR330-40.
265. Goletti D., Butera O., Bizzoni F., et al. Selective effector or memory response of RD1-specific CD4+ T cells in patients with different stages of tuberculosis. *J Infect Dis*, 2006, 194:984-992
266. Goletti D, Carrara S, Vincenti D, et al. Accuracy of an immune diagnostic assay based on RD1 selected epitopes for active tuberculosis in a clinical setting: a pilot study. *Clin Microbiol Infect*, 2006, 12:544-550.
267. Goletti D, Vincenti D, Carrara S, et al. Selected RD1 peptides for active tuberculosis diagnosis: comparison of a gamma interferon whole-blood enzyme-linked immunosorbent assay and an enzyme-linked immunospot assay. *Clin Diagn Lab Immunol*. 2005, 12:1311-1316.
268. Palmieri F, Cicalini S, Froio N, Busi Rizzi E, Macri G, Goletti D, Festa A, Petrosillo N. Pulmonary Cryptosporidiosis in an AIDS Patient: successful treatment with paromomycin plus azithromycin. *International Journal of STD&AIDS*, 2005, 189:624-633.
270. Palmieri F, Petrosillo N, Paglia MG, Conte A, Goletti D, Pucillo LP, Menegon M, Sannella A, Severini C, Majori G. Genetic confirmation of quinine-resistant *Plasmodium falciparum* malaria in a traveller from Mozambique, followed by a post-malaria neurological syndrome *Journal of Clinical Microbiology*, 2004, 42:5424-6.
271. Goletti D, Carrara S, Vincenti D, Giacomini E, Fattorini L, Garbuglia AR, Capobianchi MR, Alonzi, Fimia GM, Federico M, Poli G and Coccia E. *Mycobacterium tuberculosis* inhibits Human Immunodeficiency Virus replication in monocyte-derived macrophages. *Journal Infectious Diseases*, 2004, 189:624-33.
272. Carrara S, Vincenti D, Petrosillo N, Amicosante M, Girardi E, Goletti D. Use of a T-cell-based assay for monitoring efficacy of anti-tuberculosis therapy. *Clinical Infectious Diseases*, 2004, 38:754-6.
273. Gioia C, Agrati C, Goletti D, Vincenti D, Carrara S, Amicosante M, Casarini M, Giosue S, Puglisi G, Rossi A, Colizzi V, Pucillo LP, Poccia F. Different cytokine production and effector/memory dynamics of + or + T-cell subsets in the peripheral blood of patients with active pulmonary tuberculosis. *Int J Immunopathol Pharmacol*, 2003;16:247-252.
274. Vincenti D, Carrara S, De Mori P, Pucillo LP, Petrosillo N, Palmieri F, Armignacco O, Ippolito G, Girardi E, Amicosante M, Goletti D. Identification of early secretory antigen target-6 epitopes for the immunodiagnosis of active tuberculosis. *Mol Med*, 2003;9:105-11.
275. Antonucci G, Goletti D, Lanini S, Girardi E, Loiacono O. HIV/HCV co-infection: putting the pieces of the puzzle together. *Cell Death Differ*, 2003 Suppl 1:S25-6.
276. D'Offizi G, Ciapparoni V, Gioia C, Goletti D, Agrati C, Pucillo LP, Narciso P, Poccia F. The loss of CMV-specific CD27(-) T-cell effectors in a patient with recurrences of CMV retinitis is independent of HIV-1 viremia. *Infection*. 2002;30:323-5.
277. Martini F, Poccia F, Goletti D, Carrara S, Vincenti D, D'Offizi G, Agrati C, Ippolito G, Colizzi V, Pucillo LP, Montesano C. Acute human immunodeficiency virus replication causes a rapid and persistent impairment of Vgamma9Vdelta2 T cells in chronically infected patients undergoing structured treatment interruption. *J Infect Dis*. 2002;186:847-50.
278. Goletti D, Kinter AL, Coccia EM, Battistini A, Petrosillo N, Ippolito G, Poli G. Interleukin (IL)-4 inhibits phorbol-ester induced HIV-1 expression in chronically infected U1 cells independently from the autocrine effect of endogenous tumour necrosis factor-alpha, IL-1beta, and IL-1 receptor antagonist. *Cytokine*. 2002;17:28-35.
279. Gioia C, Agrati C, Casetti R, Cairo C, Borsellino G, Battistini L, Mancino G, Goletti D, Colizzi V, Pucillo LP, Poccia F. Lack of CD27-CD45RA-V gamma 9V delta 2+ T cell effectors in immunocompromised hosts and during active pulmonary tuberculosis. *J Immunol*. 2002;168:1484-9.

280. Mariani F, Goletti D, Ciaramella A, Martino A, Colizzi V, Fraziano M. Macrophage response to *Mycobacterium tuberculosis* during HIV infection: relationships between macrophage activation and apoptosis. *Curr Mol Med*. 2001; 2:209-16.
281. Andreoni M, Goletti D, Pezzotti P, Pozzetto A, Monini P, Sarmati L, Farchi F, Tisone G, Piazza A, Pisani F, Angelico M, Leone P, Citterio F, Ensoli B, Rezza G. Prevalence, incidence and correlates of HHV-8/KSHV infection and Kaposi's sarcoma in renal and liver transplant recipients. *J Infect*. 2001;43:195-9.
282. Girardi E, Goletti D, Antonucci G, Ippolito G. Tuberculosis and HIV: a deadly interaction. *J Biol Regul Homeost Agents*. 2001 Jul-Sep;15:218-23.
283. Monini P, Sirianni MC, Franco M, Vincenzi L, Topino S, Goletti D, Leone P, Leone P, Chiozzini C, Nicastrì E, Andreoni M, Borduagni O, Sgadari C, Rezza G, Sturzl M, Ensoli B. Clearance of human herpesvirus 8 from blood and regression of leukopenia-associated aggressive classic Kaposi's sarcoma during interferon-alpha therapy: a case report. *Clin Infect Dis*. 2001;33:1782-5.
284. Petrosillo N, Pellicelli AM, Cicalini S, Conte A, Goletti D, Palmieri F. Endocarditis caused by *Aspergillus* species in injection drug users. *Clin Infect Dis*. 2001;33:e97-9.
285. Cafaro A, Titti F, Fracasso C, Maggiorella MT, Baroncelli S, Caputo A, Goletti D, Borsetti A, Pace M, Fanales-Belasio E, Ridolfi B, Negri DR, Sernicola L, Belli R, Corrias F, Macchia I, Leone P, Michelini Z, ten Haaf P, Butto S, Verani P, Ensoli B. Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). *Vaccine*. 2001;19:2862-77.
286. Cafaro A, Caputo C, Fracasso C, Maggiorella MT, Goletti D, Baroncelli S, Pace M, Sernicola L, Koanga-Mogtomo M, Betti A, Borsetti R, Belli L, Akerblom F, Corrias S, Butto J, Heeney P, Verani F, Titti B, Ensoli B. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. *Nat Med* 5:643-50, 1999.
287. Monini P, Colombini S, Sturzl M, Goletti D, Cafaro A, Sgadari C, Butto S, Franco M, Leone P, Fais S, Leone P, Melucci-Vigo G, Chiozzini C, Carlini F, Ascherl G, Cornali E, Zietz C, Ramazzotti E, Ensoli F, Andreoni M, Pezzotti P, Rezza G, Yarchoan R, Gallo RC, Ensoli B. Reactivation and persistence of human herpesvirus-8 infection in B cells and monocytes by Th-1 cytokines increased in Kaposi's sarcoma. *Blood*. 1999 Jun 15;93(12):4044-58.
288. Monini P, Carlini F, Sturzl M, Rimessi P, Superti F, Franco M, Melucci-Vigo G, Cafaro A, Goletti D, Sgadari C, Butto S, Leone P, Chiozzini C, Barresi C, Tinari A, Bonaccorsi A, Capobianchi MR, Giuliani M, di Carlo A, Andreoni M, Rezza G, Ensoli B. Alpha interferon inhibits human herpesvirus 8 (HHV-8) reactivation in primary effusion lymphoma cells and reduces HHV-8 load in cultured peripheral blood mononuclear cells. *J Virol*. 1999 May;73(5):4029-41.
289. Goletti D, Weissman D, Jackson RW, Collins F, Kinter A, Fauci AS. The in vitro induction of human immunodeficiency virus (HIV) replication in purified protein derivative-positive HIV-infected persons by recall antigen response to *Mycobacterium tuberculosis* is the result of a balance of the effects of endogenous interleukin-2 and proinflammatory and antiinflammatory cytokines. *J Infect Dis*. 1998 May;177(5):1332-8.
290. Ostrowski MA, Stanley SK, Justement JS, Gantt K, Goletti D, Fauci AS. Increased in vitro tetanus-induced production of HIV type 1 following in vivo immunization of HIV type 1-infected individuals with tetanus toxoid. *AIDS Res Hum Reoviruses*. 1997 Apr 10;13(6):473-80.
291. Kinter AL, Ostrowski M, Goletti D, Oliva A, Weissman D, Gantt K, Hardy E, Jackson R, Ehler L, Fauci AS. HIV replication in CD4+ T cells of HIV-infected individuals is regulated by a balance between the viral suppressive effects of endogenous beta-chemokines and the viral inductive effects of other endogenous cytokines. *Proc Natl Acad Sci U S A*. 1996 Nov 26;93(24):14076-81.
292. Goletti D, Weissman D, Jackson RW, Graham NM, Vlahov D, Klein RS, Munsiff SS, Ortona L, Cauda R, Fauci AS. Effect of *Mycobacterium tuberculosis* on HIV replication. Role of immune activation. *J Immunol*. 1996 Aug 1;157(3):1271-8.
293. Goletti D, Kinter AL, Hardy EC, Poli G, Fauci AS. Modulation of endogenous IL-1 beta and IL-1 receptor antagonist results in opposing effects on HIV expression in chronically infected monocytic cells. *J Immunol*. 1996 May 1;156(9):3501-8.
294. Biswas P, Smith CA, Goletti D, Hardy EC, Jackson RW, Fauci AS. Cross-linking of CD30 induces HIV expression in chronically infected T cells. *Immunity*. 1995 Jun;2(6):587-96.
295. Goletti D, Kinter AL, Biswas P, Bende SM, Poli G, Fauci AS. Effect of cellular differentiation on cytokine-induced expression of human immunodeficiency virus in chronically infected promonocytic cells: dissociation of cellular differentiation and viral expression. *J Virol*. 1995 Apr;69(4):2540-6.
296. Cauda R, Goletti D, Lucia MB, Tumbarello M, Rumi C, Orengo AM, Moretta A. Analysis of

natural killer (NK) cell subsets defined by the expression of two novel surface antigens (EB6 and GL183) in AIDS and AIDS-related conditions. Clin Immunol Immunopathol. 1994 Mar;70(3):198-205.

297. Burastero SE, Lo Pinto G, Goletti D, Cutolo M, Burlando L, Falagiani P. Rheumatoid arthritis with monoclonal IgE rheumatoid factor. J Rheumatol. 1993 Mar;20(3):489-94.

#### Projects GRANT

2022-2025: Phase II safety trial of cysteamine for COVID-19: a new antiviral and immuno-modulating treatment funded by Italian Ministry of Health, Ricerca Finalizzata 2021

2022-2024 NIH Contract 75N93019C00067 (Subaward Number: 30049-04-208-368), "Proteome-wide characterization of T cell epitopes from Mycobacterium tuberculosis in vaccination and active infection"

2022-2026 Towards an improvement in diagnostics and treatment strategies for TB control (ADVANCE-TB), CA21164 funded by European Community.

2020-2022: BRIC: Studio degli aspetti organizzativi, immunologici e di genere per la prevenzione, diagnosi, sorveglianza e gestione dei rischi biologici occupazionali nel personale sanitario: un approccio integrato e personalizzato

2017-2018: NIH project, subcontractor, "HLA-E restricted T-cell immunity in Mycobacterium tuberculosis infection

2017-2019: PRIN, Progetto PRIN2015 20152CB22L "Ubiquitin E3 ligases as critical sensors in physiological and pathological conditions"

2019-2015: TBVAC2020; Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development , WP5 on TB biomarkers, Grant agreement ID: 643381 funded by European Community

2020-2016: European Network of Multidisciplinary Research and Translation of Autophagy knowledge (TRANSAUTOPHAGY), CA15138 funded by European Community.

2012-2014: Role of IP-10 and its truncated form in the pathogenesis of tuberculosis, Italian Ministry of Health, Ricerca Finalizzata 2012

#### Memberships International and National Society Memberships

European Respiratory Society (ERS), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Societa Italiana di Malattie Infettive e Tropicali (SIMIT)

Elected in:

ERS (European Respiratory Society), assembly 10.2 from 2012-2015, secretary

ESCMID, European Society of Clinical Microbiology and Infectious Diseases, Mycobacteria group, ESGMYC Executive Committee, Secretary from April 2015. Chair from 2017 to 2022

TBnet steering committee (responsible for the TB diagnostic area) from 2006-2012

UNION, secretary of the European Region group, from 2016; deputy chair since 2021 and ongoing

ERS, Advocacy TB Group, Secretary, 2016-2017

Member of the Collaboration for TB Vaccine Discovery (CTVD) held by the Bill and Melinda Gates Foundation, since 2016. Cochair of the Conventional T cell group from 2019 to 2022.

#### Other Relevant Information PROFESSORSHIP

Professor 06/A2-MED/02 in Medical Pathology at the UNICAMILLUS University, Faculty of Medicine since 2019.

National authorization from the Italian Ministry of Education for being full professor in Infectious Diseases and Pathology since 2013

#### PATENTS

European patent N. 1723426 on T-cell assay based on selected RD1 peptides

#### AWARD AND HONORS

Award "She made a difference 2021" from the European Women's Management Development (EWMD)

FERS. The Fellow of the European Respiratory Society (ERS) title.

Excellence in contributions to research, education and clinical leadership in respiratory medicine at



ERS

Fogarty fellowship from " J. Fogarty Association", Bethesda, Maryland

Fellowship for AIDS Research to be performed abroad funded by the Italian Ministry of Health

Fellowship to perform the specialization in Infectious Diseases (first place)

Fellowship to perform the Ph.D. program in Infectious diseases (first place)

Fellowship to perform a Clinical Training in Switzerland funded by the "Committee for cultural interchange among the universities". training at the Hopital of Neuchatel

Top Italian scientist list .Present in the list from 2014 (those with H index>30).

[http://www.topitalianscientists.org/top\\_italian\\_scientists.aspx](http://www.topitalianscientists.org/top_italian_scientists.aspx)

Top Italian women scientist list .Present in the list from 2020 (women with H index>50)..

<https://ondaosservatorio.it/it/progetto/tiws-top-italian-women-scientists/>